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ABSTRACT 
Self-renewing, chemoresistant cancer cells that contribute to cancer metastasis 
and patient relapse have properties similar to those of stem cells, and have been 
termed “cancer stem cells” (CSCs) in the literature. The identification of signaling 
pathways that regulate CSC development and/or function is an important step 
towards understanding why patients relapse, and towards development of novel 
therapeutics that specifically target CSC vulnerabilities. Recent studies have 
identified a role for the aryl hydrocarbon receptor (AHR), an environmental 
carcinogen receptor implicated in cancer initiation, in normal tissue-specific stem 
cell self-renewal. These studies inspired the hypothesis that the AHR plays a role 
in CSC development. To test this hypothesis, AHR activity in Hs578T triple 
negative and SUM149 inflammatory breast cancer cells was modulated with AHR 
ligands, shRNA, or AHR-specific inhibitors and their phenotypic, genomic, and 
  viii 
functional CSC characteristics were evaluated. Aldehyde dehydrogenase (ALDH) 
was used as an epithelial stem cell marker for flow cytometry. Results 
demonstrate that: 1) ALDHhigh cells express elevated levels of Ahr and the AHR-
driven gene that encodes cytochrome p450 isoform 1b1 (Cyp1b1), 2) AHR 
knockdown reduces ALDH activity, 3) AHR hyper-activation significantly 
increases ALDH1 activity, expression of stem cell- and invasion/migration-
associated genes, and accelerates cell migration, 4) a highly significant 
correlation between Ahr or Cyp1b1 expression (as a surrogate marker for AHR 
activity) and expression of the CSC- and invasion/migration-associated gene sets 
was seen with genomic data obtained from 79 human breast cancer cell lines 
and over 1850 primary human breast cancers, 5) the AHR interacts directly with 
the transcription factors Sox2 and Runx1, and AHR ligands increase this 
interaction, 6) AHR knockdown inhibits tumorsphere formation in low adherence 
conditions, 7) AHR inhibition blocks the rapid migration of ALDHhigh cells and 
reduces ALDHhigh cell chemoresistance, and 8) AHR knockdown inhibits tumor 
growth and reduces tumor Aldh1a1, Sox2, and Cyp1b1 expression in orthotopic 
xenografts. These data suggest that the AHR plays an important role in 
development of CSCs in a large fraction of human breast cancers and that 
environmental AHR ligands may exacerbate breast cancer by enhancing 
expression of CSC-like properties.  
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INTRODUCTION 
Breast cancer: risk factors and epidemiology  
In 1940, an American woman’s risk of getting breast cancer was 1 in 14. 
Today, 1 in 8 women will be diagnosed with breast cancer in her lifetime. Breast 
cancer is now the second most common cancer diagnosed in American women, 
with 225,000 new cases and 40,000 deaths per year (DeSantis, et al., 2011). 
There are four major classifications for breast cancer: luminal A, luminal B, 
HER2-type, and basal-like. These four types of breast cancer vary in their 
outcome, response to treatment, and risk factors (Tamimi, et al., 2012).  
Of particular interest is a subset of basal-like breast cancers called triple 
negative breast cancer (TNBC). TNBC is a human epidermal growth factor 
receptor 2-negative (HER2-), estrogen receptor-negative (ER-), and progesterone 
receptor-negative (PR-) cancer that is extremely aggressive and invasive. TNBCs 
have the highest mortality rates among the different types of breast cancer. The 
lack of hormone receptors is of particular importance because it limits valid, 
targeted therapeutic options for these patients. TNBC makes up about 15% of 
total breast cancer cases, but is disproportionately responsible for breast cancer 
deaths (Chang, et al., 2010, Duffy, et al., 2012, Foulkes, et al., 2010). It should 
also be noted that African-American and Latino women are disproportionally 
affected with TNBC compared to other ethnicities. The potential causes of these 
discrepancies are still being explored. TNBC patients typically have larger tumors 
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that are higher in grade, more aggressive, and more likely to involve metastasis 
to lymph nodes than other breast cancer subsets (De Laurentiis, et al., 2010, 
Duffy, et al., 2012, Foulkes, et al., 2010, Laurentiis, et al., 2010, Rastelli, et al., 
2010, Schneider, et al., 2008).  
Studying breast cancer in vivo 
 Currently, many in vivo murine models for breast cancer are used in 
laboratories. However, these models are unable to fully recapitulate the growth, 
progression, and metastasis of human breast cancers in vivo due to a multitude 
of differences between mouse and human biology (Kim, et al., 2004). Tumor 
biology and pathology, including location of metastases, cell micro-environments, 
tissue differentiation, hormone levels, life-span, etc., vary significantly between 
human and murine models (Kim, et al., 2004). Xenografts, a graft of a tissue from 
one species to a foreign species, first started being performed in 1962 to control 
for some of the variants between mouse and human cancer biology (Kim, et al., 
2004).  However, xenografts must be performed in an immunodeficient mouse, 
which creates an additional variable of having an altered immune system in the 
mouse model (Kim, et al., 2004). Traditional xenograft models, such as tail vein 
injection and mammary fat pad injection with wild-type cell lines, are technically 
challenging and do not always lead to successful tumor formation, nor do they 
fully recapitulate human breast cancer biology. Newer murine breast cancer 
models, such as intra-cardiac injection, primary cell implantation following 
surgical removal from a human patient, and engraftment of a three-dimensional 
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model including fibroblasts aim to increase success rates of tumor engraftment 
and to more closely resemble human breast cancer (Kim, et al., 2004, Sheridan, 
et al., 2006). In order to increase the rate of successful xenografts, a 
ALDH1high/CD44+/CD24- cell population has been identified that seeds tumors 
more efficiently then the wild-type cell line xenografts (Al-Hajj, et al., 2003).  
Breast cancer risk factors 
In general, the number one risk factor for breast cancer is age, with 
women over the age of 70 having the highest risk of being diagnosed with breast 
cancer. Many other factors have been implicated in breast cancer risk as well, 
such as genetics, breast density, family history, nutrition, radiation therapy, race, 
use of alcohol, reproductive and menstrual history, body weight, use of hormone 
replacement therapies, exercise and use of prescription medications such as 
diethylstilbestrol (Howlader N, 2011). Significantly, analyses of these known risk 
factors do not fully explain the increase in breast cancer incidence seen since 
1940, nor the genesis of ~90% of breast cancers that are not related to the 
inheritance of susceptibility genes. These and other studies (Dusich, et al., 1980) 
inspired the hypothesis that exposure to environmental chemicals, such as aryl 
hydrocarbon receptor (AHR) modulators, contributes to breast cancer 
(DiAugustine and Davis, 1993, Morris and Seifter, 1992, Rogers and Conner, 
1990, Trombino, et al., 2000). 
Breast cancer and the environment 
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In 2009, the President’s Cancer Panel concluded that, “…the true burden 
of environmentally induced cancer has been grossly underestimated” (Leffall and 
Kripke, 2010). Since that time, more research has been focused on the role of 
environmental chemicals in initiating and exacerbating cancers (Audouze, et al., 
2010, Benigni and Bossa, 2011, Ovesen, et al., 2014, Rudel, et al., 2011, 
Williams, 2012, Zhang, et al., 2011). While exposure to genotoxic environmental 
chemicals has frequently been associated with gene mutations and increased 
incidence of several types of cancers, including breast cancer (Ahn, et al., 2006, 
Belpomme, et al., 2007, Brody, et al., 2007, Eldrige, 2006, Faraglia, et al., 2003, 
Gammon, et al., 2002, Mordukhovich, et al., 2010, Santella, et al., 2005), the 
molecular mechanisms through which non-genotoxic chemicals contribute to 
cancer progression remain unclear.  
Given the emerging evidence that common environmental carcinogens 
play a significant role in cancer (Leffall and Kripke, 2010), increased attention 
has been paid to molecular mechanisms through which pollutants affect tumor 
formation or progression (Benigni and Bossa, 2011, Rudel, et al., 2011, Williams, 
2012). Historically, most studies on environmental chemical carcinogenesis 
centered on the ability of genotoxic chemicals to damage DNA, induce mutations, 
and initiate cancers (Brody, et al., 2007, Eldrige, 2006, Mordukhovich, et al., 
2010). However, recent data suggest complementary, non-genotoxic pathways 
involving cellular receptors, which can be activated by environmental ligands and 
eventually lead to cancer. Importantly, a meta-analysis of over 150 published 
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studies on breast cancer and the environment implicates a number of 
environmental chemicals, including AHR ligands, in breast cancer risk (Brody, et 
al., 2007). This conclusion is supported by laboratory studies (Barnabas, et al., 
1995, Calaf and Russo, 1993, Currier, et al., 2005, Kavanagh, et al., 2001, 
Russo, et al., 1993, Russo and Russo, 1996, Russo, et al., 2002, Schlezinger, et 
al., 2006, Shin, et al., 2006, Trombino, et al., 2000).   
The aryl hydrocarbon receptor (AHR) 
The per/ARNT/Sim (PAS) family of transcription factors all of play 
important physiological roles (e.g., angiogenesis, circadian rhythms). The AHR is 
the only ligand-activated member of the PAS family (Furness, et al., 2007, 
Furness and Whelan, 2009). In its unliganded state, the AHR forms a 
heterodimer with a dimer of the molecular chaperone hsp90, one molecule of the 
hsp90 co-chaperone p23, and one molecule of an immunophilin like protein 
termed Ara9/AIP/XAP2.  A lipophilic ligand will bind to the AHR, which is located 
in the cytoplasm, resulting in a conformational change that reveals its nuclear 
localization signal. Once the AHR enters the nucleus, the chaperone complex is 
exchanged for the aryl hydrocarbon receptor nuclear translocator (ARNT) 
(Nebert, et al., 1999). The AHR/ARNT heterodimer can then recognize aryl 
hydrocarbon response elements (AHREs) of target genes with the consensus 
sequence 5’-TNGCGTG-3’ in the promoter region of responsive genes (Sun, 
2004).  Some of these genes, which are often referred to as the AHR gene 
battery, encode enzymes that are involved in the metabolism of xenobiotics and 
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endogenous compounds including phase I enzymes, CYP1A1, CYP1A2, and 
CYP1B1, as well as several phase II enzymes (Nebert, et al., 1999).  
The AHR also regulates genes encoding the c-Myc oncoprotein in breast 
tumors (Yang, et al., 2005), the pro-apoptotic protein Bax in the ovary 
(Matikainen, et al., 2001, Matikainen, et al., 2002), the AHR repressor (AHRR), 
and the protein kinase CK2 (Belguise, et al., 2007, Hahn, et al., 2009), all of 
which have been implicated in breast cancer (Dietrich and Kaina, 2010). 
Additionally, the AHR has been implicated in regulation of various other 
transcription factors (e.g. NF-κB), in the modulation of estrogen receptor activity, 
in the regulation of cytokine gene transcription, and in the control of cell growth 
(Dietrich and Kaina, 2010). With a hand in the control of such a vast array of 
genes, the AHR is positioned at the apex of a network of intracellular interactions 
that could contribute significantly to malignant transformation and breast cancer 
through multiple mechanisms. AHR signaling can be terminated by exposing the 
nuclear export sequence (NES) after the AHR disassociates with ARNT following 
transcription of the AHR gene battery (Ikuta, et al., 1998). Exposure of the NES 
leads the AHR to be shuttled to the cytoplasm where it is rapidly degraded by the 
proteasome (Davarinos and Pollenz, 1999). In addition, AHR activation leads to 
transcription of the AHRR, which negatively regulates AHR signaling. The AHRR 
can form a dimer with the AHR and prevent binding to AHREs and DNA binding. 
The AHRR can also act as a transrepressor of the AHR-ARNT complex, down 
regulating AHR-mediated transcription of the AHR gene battery (Evans, et al., 
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2008).   
 The AHR is widely studied for its role in the induction and transcriptional 
regulation of genes encoding cytochrome P450 enzymes, which metabolize 
some environmental chemicals into reactive mutagenic metabolites (Currier, et 
al., 2005, Kavanagh, et al., 2001, Kim, et al., 2000, Murray, et al., 2005, Murray, 
et al., 2006, Schlezinger, et al., 2006, Shin, et al., 2006, Trombino, et al., 2000, 
Yang, et al., 2005, Yang, X., et al., 2008). Activators of the AHR include 
environmental dioxins, polychlorinated biphenyls (PCBs) and polycyclic aromatic 
hydrocarbons (PAHs) (Furness and Whelan, 2009), all of which are high priority 
chemicals on the U.S. Agency for Toxic Substances and Disease Registry 
(ATSDR)  list of pollutants of greatest concern to human health  
(http://www.atsdr.cdc.gov/SPL/resources/).  
Breast cancer and the AHR  
Indeed, there are now many studies that demonstrate an association 
between exposure to AHR ligands and breast cancer risk (DiAugustine and 
Davis, 1993, Dusich, et al., 1980, Falk, et al., 1992, Hunter, et al., 1997, Li, et al., 
1999, Morris and Seifter, 1992, Wassermann, et al., 1976), particularly in 
genetically susceptible women (Laden, et al., 2002, Li, et al., 1999, Li, et al., 
2005, Negri, et al., 2003, Santella, et al., 2005, Shen, et al., 2006, Shen, et al., 
2005, Terry, et al., 2004). These and other studies (Dusich, et al., 1980) inspired 
the hypothesis that exposure to environmental chemicals contributes to breast 
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cancer (DiAugustine and Davis, 1993, Morris and Seifter, 1992, Rogers and 
Conner, 1990, Trombino, et al., 2000). More recent work suggests that the AHR, 
which is expressed at aberrantly high levels and is chronically active in several 
cancers in the absence of environmental stimuli, plays an ongoing role in tumor 
progression by enhancing tumor invasion and metastasis (Brooks and Eltom, 
2011, Goode, et al., 2013, Safe, et al., 2013, Schlezinger, et al., 2006, Shin, et 
al., 2006, Yang, et al., 2005, Yang, X., et al., 2008). Furthermore, AHR-driven 
Cyp1b1 was found to be highly expressed in many tumors, however the healthy 
surrounding tissue had little or no Cyp1b1 expression (Murray, et al., 2001, 
Murray, et al., 1997). This contribution of the AHR to invasion and metastasis is 
influenced by endogenous ligands, which chronically drive AHR transcriptional 
activity (Chang, 1998, Marlowe and Puga, 2005, Opitz, et al., 2011, Powell, et al., 
2013).  
Here, it is postulated that environmental AHR ligands mimic this effect and 
drive cancer progression, at least in part, by increasing the development and/or 
function of cells with cancer stem cell (CSC) properties.  The demonstration that 
an environmental chemical receptor is involved in both early (mutation-
dependent initiation) and late (tumor invasion) events during mammary 
tumorigenesis, represents a major paradigm shift from previous models in which 
genetic mutation was seen as the only mechanism through which AHR ligands 
contribute to malignancy. It also suggests that exposure of at-risk populations to 
environmental chemicals, perhaps even before cancer detection, may contribute 
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to significantly worsened outcomes.  Additionally, exposures late in the disease 
process, during transition from a benign tumor into a lethal, metastatic cancer, 
may also contribute to significantly worsened outcomes.  
Several laboratories, including our own, exploited rodent models of 
mammary tumorigenesis in which cancers were preferentially induced in the 
mammary gland following oral exposure to AHR ligands (Currier, et al., 2005, 
Jerry, et al., 2000, Kim, et al., 2000, Russo and Russo, 1996, Trombino, et al., 
2000). We demonstrated a remarkable 40-fold increase in Ahr mRNA in rat 
mammary tumors relative to normal mammary tissue after rats were exposed to 
DMBA, a potent AHR agonist (Schlezinger, et al., 2006, Trombino, et al., 2000). 
Additional follow-up computational analyses of microarray data from over 50 
human breast cancer cell lines in the Cancer Cell Line Encyclopedia (Barretina, 
et al., 2012) confirmed Ahr up-regulation in virtually all cancer cell lines evaluated 
(Narasimhan, et al., 2015). Our studies demonstrate that constitutively 
(endogenous ligand-activated) active AHR drives immortalized mammary 
epithelial cell growth (data not shown) and triple negative breast cancer cell 
invasion (Narasimhan, et al., 2015).   
 
AHR Modulators and the Great Debate 
There are four main classes of AHR modulators that are currently being 
studied: agonists, antagonists, selective modulators, and indirect regulators. 
Agonists are defined by their ability to bind to the AHR and cause an increase in 
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expression of the AHR gene battery. There are two major categories of AHR 
agonists, synthetic and natural. Synthetic agonists are the “traditional” AHR 
environmental ligands, including PCBs, PAHs and dioxins, which activate the 
canonical AHR signaling pathway (Safe, 1990). Natural AHR agonists include 
plant-derived flavonoids and indole-3-carbinol found in cruciferous vegetables 
(Ashida, et al., 2000, Bjeldanes, et al., 1991, Zhang, et al., 2003). A subset of 
natural AHR ligands that are widely studied is endogenous ligands, which are 
produced within the body. Endogenous AHR ligands may be what is controlling 
baseline AHR expression and activity in the human body. Endogenous ligands 
include tryptophan metabolites, such as FICZ, kynurenic acid, kynurenine, and 
indoxyl sulfate (Dinatale, et al., 2010, Opitz, et al., 2011, Schroeder, et al., 2010, 
Wincent, et al., 2008), as well as microbiome-derived tryptophan metabolites 
such as tryptamine, indole-3-acetate and indole (Jin, et al., 2014). It also should 
be noted that AHR agonists have a range of affinities and abilities to activate the 
AHR to its maximal activity level. For example, a weak agonist will exhibit 
antagonist activity in the presence of a strong agonist because it is competing 
with strong AHR agonists to bind to the AHR ligand binding domain (Murray, et 
al., 2014). 
Competitive AHR antagonists are able to prevent agonists from binding to 
the ligand-binding pocket and the subsequent conformational change that 
occurs, thereby blocking AHR signaling. Several AHR antagonists have been 
synthesized, including the gold standard CH223191 (Kim, S, et al., 2006) and 
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CB7993113, characterized by our lab (Parks, et al., 2014). To characterize 
potential partial agonists and antagonists, the ability of a compound to induce 
AHR activity over a full dose range with and without a competitive binding ligand 
is tested. Partial agonists are able to activate the AHR at high concentrations, 
while AHR antagonists are unable to activate the AHR at any concentration (Jin, 
et al., 2012).  
Selective AHR modulators, also known as SAHRMs, are ligands that bind 
to the AHR and drive AHR transcriptional activity. SAHRMs can both increase 
and decrease gene expression, therefore avoiding classification as a true agonist 
or antagonist (Murray, et al., 2014, Patel, et al., 2009, Safe, et al., 1999). 
SAHRMs have the unique ability to induce AHR nuclear translocation and 
AHR/ARNT dimerization, but actually mediate the expression of an alternate set 
of biological outcomes without binding to an AHRE. SAHRMs also have the 
unique ability to either act as an antagonist by competitively inhibiting agonist 
binding, or as an agonist in other contexts (Jin, et al., 2012). Several SAHRMs 
have been discovered and are currently in clinical trials as a therapeutic for solid 
tumors, including an I3C derivative 3,3'-Diindolylmethane (DIM) and 6-methyl-
1,3,-trichlorodibenzofuran (MCDF) (Zhang, et al., 2012). By determining if 
nuclear translocation is occurring, one can make the distinction between 
SAHRMs and antagonists; SAHRMs will induce AHR nuclear translocation while 
AHR antagonists will not induce nuclear translocation (Jin, et al., 2012). 
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Finally, indirect regulators are able to modify AHR signaling independent 
of binding directly to the ligand-binding domain. How this phenomenon occurs is 
still being determined, but it is hypothesized that indirect regulators can bind 
directly to chaperone proteins or alter phosphorylation cascades. Two examples 
of indirect regulators of the AHR include the benzimidazole omeprazole (Kikuchi, 
et al., 1998), which has been shown to enhance AHR signaling, and the green 
tea polyphenol epigallocatechin gallate (EGCG) (Palermo, et al., 2005), which 
has been shown to inhibit AHR signaling.  
Currently, both AHR agonists and antagonists are being studied as 
potential breast cancer therapeutics. How both AHR agonists and antagonists 
could be beneficial to cancer patients is still being evaluated. So far, there are 
two potential theories of why both AHR agonists and antagonists may be 
potential chemotherapeutics, the diversion theory and the partial agonist theory. 
The diversion theory states that endogenous ligands drive the AHR to increase 
tumor growth and metastasis. Adding in an exogenous ligand drives the signaling 
pathway in another direction that is not involved with cell growth and metastasis 
(Schlezinger, et al., 2006). On the other hand, the partial agonist theory states 
that weak exogenous AHR agonists can sometimes act as inhibitors if the 
endogenous agonist(s) has a higher affinity for the AHR than the exogenous 
agonist. In this case, the weak exogenous agonist competes with the strong 
endogenous agonist, although it does not deliver as strong a signal. Hence, the 
exogenous agonist reduces the effect of the endogenous agonist and acts 
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similarly to an inhibitor. 
For this project, we have studied both AHR agonists and antagonists. 
AHR expression or activity was modulated with a doxycycline (dox)-inducible 
Ahr-specific shRNA (shAhr), AHR inhibitors (CH223191 and CB7993113) (Choi, 
et al., 2011, Kim, SH, et al., 2006, Parks, et al., 2014), or four AHR agonists: 1) 
6-formylindolo[3,2-b]carbazole (FICZ), a high affinity AHR ligand, tryptophan 
photo-metabolite and potential endogenous ligand (Jönsson, et al., 2009), 2) β-
NF, a flavone with moderate affinity for the AHR,  3) 2,3,7,8-
tetrachlorodibenzo(p)dioxin (TCDD), a high affinity, persistent environmental 
AHR ligand and “gold standard” AHR ligand, and 4) 7,12 
dimethylbenzanthracene (DMBA), a readily metabolizable polycyclic aromatic 
hydrocarbon.  
The AHR and Stem Cells 
Here, the possible role of the AHR, previously linked to invasion and 
metastasis, in the development and function of cancer stem cells (CSCs) in 
models of aggressive, metastatic triple negative and inflammatory breast cancers 
was tested. The involvement of the AHR in CSC biology is suggested by its 
emerging role in normal tissue-specific stem cell development. The AHR plays an 
important role in tissue-specific embryonic development, hematopoietic stem cell 
self-renewal, pluripotent stem cell and neural stem cell differentiation, and 
megakaryocyte/erythroid stem cell growth (Gasiewicz, et al., 2014, Ko, et al., 
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2014, Singh, et al., 2014, Singh, et al., 2011, Smith, et al., 2013, Wang, Qin, et 
al., 2013). For example, the AHR, presumably activated by endogenous 
ligand(s), helps maintain hematopoietic progenitor cell (HSC) self-renewal, 
blocking potential HSC differentiation (Boitano, et al., 2010, Lindsey and 
Papoutsakis, 2012, Singh, et al., 2014, Singh, et al., 2011). An AHR antagonist, 
SR1, was found to affect the maintenance of CD34+, CD133+ and CD90+ 
hematopoietic stem and progenitor populations. Removal of this AHR antagonist 
leads to the differentiation of these cell progenitor populations, directly implicating 
the AHR in HSC differentiation (Boitano, et al., 2010). Indeed, AHR expression in 
HSC correlates with expression of several stem cell-associated genes, some of 
which were studied here, including Aldh1a1 (Gasparetto, et al., 2012, Smith, et 
al., 2013). The AHR also drives bi-potential blood progenitor cell differentiation, 
with AHR agonism leading to erythroid differentiation and AHR antagonism 
leading to differentiation into megakaryocytes (Smith, et al., 2013).  
As seen in the study of AHR’s role in cancer biology, all agonists do not 
always lead to the same outcomes. Agonists B(a)P and DMBA differentially 
affect bone marrow cells, as shown by Galván, et al (Galván, et al., 2006). They 
found that following intraperitoneal DMBA treatment, total bone marrow cellularity 
quantitatively decreased, while B(a)P exposure did not affect overall cellularity. 
However, B(a)P treatment led to a shift within bone marrow lineages, including a 
decrease in pro/pre B-lymphocytes and an increase in monocyte counts, while 
immature and mature B-lymphocyte development was unaffected. DMBA 
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exposure led to an increase in hematopoietic stem cells, while the number of 
committed myeloid and lymphoid lineage cells decreased. Specifically, DMBA 
exposure led to a decrease in pro/pre B-lymphocytes, immature B-lymphocytes, 
GR-1+ cells, monocyte and neutrophils, while mature B-lymphocytes were 
unaffected (Galván, et al., 2006). 
Further studies on the role of AHR in HSCs found that TCDD treatment 
led to altered function, phenotypic characteristics and numbers of HSCs 
(Gasiewicz, et al., 2014). Ahr-/- knockout mice exhibit lower white and red blood 
cells numbers. Additionally, Ahr-/- knockout mice HSCs were found to be hyper-
proliferative, eventually leading to pre-mature HSC exhaustion (Gasiewicz, et al., 
2014, Singh, et al., 2014, Singh, et al., 2011). The bone marrow from the Ahr-/- 
knockout mice exhibits increased stem/progenitor and lineage-committed cells, 
while there is actually a decrease in erythroid progenitor cells (Singh, et al., 
2011). These observations implicate AHR activity in the control and regulation of 
HSC proliferation and quiescence (Gasiewicz, et al., 2014, Singh, et al., 2014). In 
summary, the AHR plays a key role in HSC biology, and improper AHR signaling 
may lead to blood and aging related diseases (Singh, et al., 2009).  
Looking at other stem cell lineages affected by AHR signaling, Puga’s 
group has been exploring the role of AHR repression in maintaining pluripotent 
embryonic stem cells and the role of the AHR signaling in embryonic stem cell 
differentiation into cardiomyocytes (Ko, et al., 2014, Wang, Qin, et al., 2013).  
The AHR is silenced in mouse embryonic stem cells, but expression is necessary 
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for cells to differentiate into more specialized roles (Ko, et al., 2014). Follow-up 
analyses studying directed differentiation found that treating embryonic stem 
cells with TCDD, an AHR agonist, decreased the development of contractile 
cardiomyocytes (Wang, Qin, et al., 2013). In addition, treatment with an AHR 
agonist or antagonist led to altered gene expression of many genes critical to 
stem cell pathways, implicating the AHR in cardiovascular development (Wang, 
Qin, et al., 2013).  
The AHR also has been shown to play a critical role in neural precursor 
cell development. Exposure to TCDD led to altered neural precursor cell 
proliferation, and thereby impedes the development of neurons and total brain 
mass (Latchney, et al., 2011). Further experimentation is required to determine 
the exact windows of development where the AHR plays a role in neuronal 
development, and to further determine the role of the AHR in neurogenesis 
(Latchney, et al., 2011). All these studies have shown that the AHR is an 
important controller of stem cells in general, making further research on the role 
and function of the AHR in CSCs an important area of study. 
Markers and Characteristics of Cancer Stem Cells (CSCs) 
Recent evidence suggests that invasion and metastasis leading to patient 
death is mediated, to a disproportionate extent, by chemoresistant, long-lived 
cancer stem cells (CSCs), sometimes referred to as tumor-initiating cells (Al-Hajj, 
et al., 2003, Charafe-Jauffret, et al., 2010, Charafe-Jauffret, et al., 2009, 
Economopoulou, et al., 2012, Gangopadhyay, et al., 2012, Ginestier, et al., 2007, 
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Lobo, et al., 2007, Nguyen, et al., 2009). Indeed, cancer can recur years after an 
ostensibly successful treatment. In 2001 Reya et al. first published the 
hypothesis that cancer may arise from mutations in tissue specific stem cells, 
which have the ability to self-renew and differentiate into multiple cell types. 
(Reya, et al., 2001). Mammary stem cells are required for the development of 
and changes within the mammary gland. The mammary gland undergoes the 
majority of its development after birth, and changes throughout a woman’s life, 
especially during pregnancy. The constantly changing nature of the mammary 
gland requires committed adult stem cells to achieve such plasticity (Charafe-
Jauffret, et al., 2008). It is hypothesized that CSCs are able to highjack the self-
renewal and differentiation machinery found in tissue-specific stem cells to drive 
tumorigenesis (Reya, et al., 2001).  
The ability to isolate mammary stem cells allowed for further study of 
BCSCs, aggressive cells that were hypothesized to have either developed from 
mutated mammary stem cells that had undergone an oncogenic transformation 
or from de-differentiated and mutated early progenitor cells (Charafe-Jauffret, et 
al., 2008, Reya, et al., 2001). In 2003, mammary stem cells were first grown in 
three-dimensional culture, termed mammospheres. Following similar protocols 
for neuronal stem cells that were enriched in neurospheres, mammary epithelial 
cells were cultured in suspension on non-adherent surfaces with the addition of 
growth factors, including B27, epidermal growth factor, and basic fibroblast 
growth factor, forming mammospheres (Dontu, et al., 2003). The transcriptional 
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profiles of mammospheres was found to significantly overlap with profiles of 
defined stem cells, piquing interest in studying breast cancer stem cells (BCSCs) 
(Dontu, et al., 2003). Further studies identified markers for BCSCs, including the 
ability to form mammospheres, elevated ALDH1 activity, increased expression of 
traditional stem cell markers and invasion- and metastasis-markers, increased 
tumorigenesis in vivo, and chemotherapeutic resistance. 
In 2007, Ginestier et al. first identified a detoxifying enzyme, ALDH1, as a 
potential functional BCSC marker (Ginestier, et al., 2007). ALDH1 is involved in 
differentiation of stem cells by oxidizing retinol to retinoic acid (Chute, et al., 
2006) and is also believed to play a role in breast cancer chemoresistance 
(Croker, et al., 2009). Cells that are isolated based on having high ALDH1 activity 
have both phenotypic and functional characteristics of BCSCs, including the 
ability to self-renew, recapitulate the cellular diversity of the original tumor, and 
form tumors following in vivo transplantation at very low cells numbers (Charafe-
Jauffret, et al., 2008, Ginestier, et al., 2007). In contrast, cells with low levels of 
ALDH1 are not able to form tumors in vivo when transplanted with very low cell 
numbers (Charafe-Jauffret, et al., 2008, Ginestier, et al., 2007). Additionally, 
ALDH1 expression is a strong marker of poor clinical outcome (Charafe-Jauffret, 
et al., 2010, Ginestier, et al., 2007). Other markers, including the relative levels of 
CD44 and CD24 expression, have been used to identify CSC subsets (Al-Hajj, et 
al., 2003, Wicha, et al., 2003), however ALDH expression and activity may be a 
more selective functional marker for some CSC types (i.e., breast cancer stem 
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cells) (Charafe-Jauffret, et al., 2010, Charafe-Jauffret, et al., 2008, Croker and 
Allan, 2011, Croker, et al., 2009, Ginestier, et al., 2007, Landen, et al., 2010). 
More recently, new markers and pathways have been explored to identify 
CSCs (Lu, et al., 2013, Paranjape, et al., 2014, Tang, et al., 2015, Wang, et al., 
2015), to define the CSC population cell of origin (White and Lowry, 2015), and 
to enrich CSC populations (Donnenberg and Donnenberg, 2015, Lu, et al., 2013, 
Nishi, et al., 2013, Schmidt, et al., 2015, Wang, et al., White and Lowry, 2015).  
Importantly, Tang et al. developed a hybrid SOX2 and OCT4 reporter, which 
allows for the identification and monitoring of CSCs in their microenvironment. 
Also, this reporter allows for CSC tumorigenicity, plasticity and chemotherapeutic 
resistance to be studied in real-time while monitoring the expression of traditional 
stem cell markers in vivo and in vitro settings (Tang, et al., 2015). Another 
potential potent marker for CSCs is PROCR. Cells expressing high levels of 
Procr have been identified to be enriched in their ability to self renew in 
transplantation assays and differentiate into the lineages of the mammary 
epithelium via lineage tracing studies (Wang, et al., 2015). A number of papers 
have also shown that inducing epithelial to mesenchymal transition by induction 
of traditional stem cell markers such as NANOG, C-MYC, KLF4, OCT4, and 
SOX2 in cells leads to an increase in the CSC population (Nishi, et al., 2013, 
Paranjape, et al., 2014, Wang, et al., 2015, Wang, et al.), similar to earlier 
findings by Mani et al. (Mani, et al., 2008). These recent papers have implicated 
traditional stem cell markers in induction of CSCs through inducing 
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dedifferentiation, a mesenchymal phenotype, and an increased resistance to 
chemotherapeutics, identifying them as valuable markers for CSCs. 
BCSCs can be defined by: 1) expression of genes associated with 
“normal” tissue stem cells (e.g., Notch1,2, Sox2, Pou5F1/Oct4) and with invasion 
and migration (e.g., Twist1,2, Vim, Snai1,2) (Bolós, et al., 2009, Chiou, et al., 
2010, Ferrari, et al., 2014, Leis, et al., 2011, Mani, et al., 2008, Scheel and 
Weinberg, 2012), 2) formation of mammospheres in ultra-low adherence cultures 
(Wicha, et al., 2003), 3) elevated levels of aldehyde dehydrogenases (ALDH), 
enzymes associated with chemoresistance, high histological tumor grade, and 
poor prognoses (Charafe-Jauffret, et al., 2010, Economopoulou, et al., 2012, 
Tanei, et al., 2009), 4) the propensity to self-renew while spawning progenitor 
cells (Reya, et al., 2001, Wicha, et al., 2003), 5) chemoresistance (Clevers, 2011, 
Croker and Allan, 2011, Economopoulou, et al., 2012, Fillmore and Kuperwasser, 
2008, Gangopadhyay, et al., 2012, Li, et al., 2008, Qiu, et al., 2013) 6) increased 
invasion and migration (Mani, et al., 2008), and 7) an increased efficiency of 
tumor formation in xenografts (Reya, et al., 2001, Wicha, et al., 2003).  Clearly, 
identifying factors responsible for development of BCSCs is an important step 
towards understanding why many patients relapse, even several years after 
going into remission.  
Most germane to the studies proposed here is the demonstration that the 
AHR, expressed in high levels in relatively aggressive TNBC cells (Murray, et al., 
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2006, Yang, et al., 2005, Yang, X., et al., 2008), is constitutively active, driving 
expression of both phenotypic (ALDH expression) and functional (mammosphere 
formation, chemoresistance) markers of BCSCs. These important results suggest 
that exposure to environmental chemicals and the subsequent activation of the 
AHR contributes to BCSC development, maintenance and/or function. 
Furthermore, this brings forth the intriguing possibility that environmental AHR 
ligands may exacerbate this process, potentially even before overt tumors are 
detected. 
Genes of interest in breast cancer stem cells 
Many genes have been implicated in generating both normal tissue 
specific stem cells and CSCs. It is important to note that where information was 
available, all of the genes mentioned here, excluding ALDH1A1, have AHREs in 
their promoter region where the AHR could potentially be binding and controlling 
expression of said key genes (Aim 1, Table 1). NOTCH1 and NOTCH2 are 
critical to symmetric and asymmetric cell division, and stem cell differentiation in 
embryonic and adult stem cells (Bolós, et al., 2009, Simmons, et al., 2012). The 
Notch signaling pathway is also directly implicated in mammary stem-cell self-
renewal and branching morphogenesis (Dontu, et al., 2003, Dontu and Wicha, 
2005). Importantly, NOTCH1 and NOTCH2 are aberrantly regulated in mammary 
stem cells and BCSCs (Farnie and Clarke, 2007). Additional studies also have 
found that NOTCH1 and NOTCH2 are able to aid in resistance to 
chemotherapeutic-induced cell apoptosis (as reviewed in (Bolós, et al., 2009)) 
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and may be an important target for CSC-specific breast cancer therapeutics 
(Farnie and Clarke, 2007, Hombach-Klonisch, et al., 2008, Mao, et al., 2013, 
Pannuti, et al., 2010, Qiu, et al., 2013).  
Bmi1 was found to be required for the maintenance of somatic stem cells 
through repression of cellular senescence and cell death (Park, et al., 2004). 
BMI1 also is involved in the control of CSC growth, chemoresistance and 
tumorsphere formation (Paranjape, et al.). Bmi1 was found to be expressed at 
higher levels in undifferentiated versus differentiated mammary cells, acting as a 
marker for mammary stem cells. Furthermore, overexpression of Bmi1 led to an 
increase in mammary stem cell self-renewal and proliferation (Liu, et al., 2006). 
Stella is involved in maintenance of gene-specific DNA methylation in the early 
embryo, and is a marker for some CSC types (Ezeh, et al., 2005). SOX2, OCT4 
and NANOG are traditional embryonic stem cell markers used to reprogram cells 
to a pluripotent state, and are expressed at elevated levels in CSCs (Chiou, et 
al., 2010, Ezeh, et al., 2005, Leis, et al., 2011, Takahashi and Yamanaka, 2006). 
SOX2 is up-regulated in TNBCs and has been implicated in tumorsphere 
formation and control of tumor initiation (Leis, et al., 2011, Liang, et al., 2013, 
Rodriguez-Pinilla, et al., 2007, Wu, et al., 2012). Further studies have shown that 
Sox2 is preferentially expressed in basal-like breast cancers (Rodriguez-Pinilla, 
et al., 2007), and that expression levels can be indicative of metastatic potential 
(Lengerke, et al., 2011). SOX2 has been directly implicated in increasing both 
breast cancer proliferation and tumorigenesis by increasing CCND1 levels and 
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aiding in the G1/S phase transition (Chen, et al., 2008). Oct4 expression has 
been found to be increased in normal tissue stem cells as well as CSCs, and has 
been associated with the proliferation and maintenance of CSCs (Tai, 2004, 
Zhao, et al., 2015).  Both OCT4 and NANOG serve as biomarkers of a poor 
breast cancer prognosis, as well as being key players in cancer metastasis (Lu, 
et al., 2013, Wang, et al., 2014). NANOG is also being studied as a potential 
therapeutic target for the treatment of NANOG-expressing metastatic breast 
cancers (Lu, et al., 2013). Runx1 is another potential novel marker of BCSCs and 
aggressive TNBCs, and is being studied as a potential therapeutic target (Ferrari, 
et al., 2014).  
There is also a large number of invasion- and cell migration-associated 
genes linked to BCSCs including Snail, Slug, Twist1, Twist2, Tgfb1, Vimentin and 
Fibronectin (Fn1) (Battula, et al., 2010, Mani, et al., 2008, Morel, et al., 2008). 
SNAIL is a transcription factor that is up-regulated in a number of different types 
of cancer, including breast cancer, and is directly associated with invasion and 
migration (McGrail, et al., 2014, Smith, et al., 2014). SNAIL is believed to repress 
E-cadherin and to activate ERK2, leading to increased cell motility and a 
decrease in cell adhesion (McGrail, et al., 2014, Smith, et al., 2014). SLUG is 
another master transcriptional regulator involved in the transition from an 
epithelial phenotype to a mesenchymal phenotype (Mani, et al., 2008, Scheel 
and Weinberg, 2012). It has been shown that SLUG expression is partially 
regulated by the AHR signaling pathway (Belguise, et al., 2007).  Ectopic 
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expression of TWIST1 and TWIST2 in breast cancer cells leads to an invasive 
phenotype with the ability to migrate, as well an increase in functional markers for 
CSCs, including tumorsphere formation (Fang, et al., 2011, Kong, et al., 2015, 
Scheel and Weinberg, 2012, Schmidt, et al., 2015). Elevated levels of TWIST1 
and TWIST2 are implicated in self-renewal and invasion (Schmidt, et al., 2015), 
making them potential targets of the AHR signaling pathway, which also plays an 
important role in cell invasion and self-renewal.  
High levels of TGFB1 have been widely linked to aggressive, invasive 
breast cancers. Additionally, it has been shown that blocking and/or targeting 
Tgfb1 expression leads to cancer cell death (Bhola, et al., 2013, Fang, et al., 
2012). The known role of TGFB1 in cell invasion and migration makes it a key 
target of cancer research and a potential important player in BCSC targeted 
therapeutic development (Romagnoli, et al., 2012, Wiercinska, et al., 2010). 
VIMENTIN is a mesenchymal marker, which is up-regulated in BCSC; Vimentin 
expression has been correlated with carcinomas formed from mammary 
progenitor cells with bi-potent differentiation capabilities (Charafe-Jauffret, et al., 
2008, Mani, et al., 2008). Finally, FIBRONECTIN expression is increased in 
invasive and metastatic cells, acting as a marker for mesenchymal cells (Dietrich 
and Kaina, 2010). It was found that cells expressing higher levels of Fibronectin 
share similar phenotypes and genotypes to BCSCs (Mani, et al., 2008). All of 
these markers may potentially be regulated by the AHR, and further studies will 
aim to determine the hierarchy and signaling mechanics among the AHR and 
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these markers. 
AHR and Breast CSCs (BCSCs) 
Here, the role of the AHR in the development and function of CSCs in 
models of aggressive, metastatic triple negative and inflammatory breast cancers 
was tested. Our suspicion that the AHR was involved in CSC biology was piqued 
by the demonstration that the AHR plays an important role in tissue-specific 
embryonic development, hematopoietic stem cell self-renewal, differentiation of 
pluripotent stem cells into cardiomyocytes, and neural stem cell differentiation 
(Gasiewicz, et al., 2014, Ko, et al., 2014, Latchney, et al., 2011, Singh, et al., 
2014, Singh, et al., 2011, Wang, Qin, et al., 2013). The hypothesis that the AHR 
influences breast CSC biology and that environmental AHR ligands exacerbate 
those effects was tested using two aggressive, metastatic breast cancer cell 
lines: Hs578T, a TNBC cell line, and SUM149, an inflammatory breast cancer 
(IBC) cell line. Results from those cell lines were compared with genomic 
outcomes in 79 breast cancer cell lines and >1850 primary cancers using 
computational modeling to confirm that our findings were generalizable to other 
primary breast cancer cell lines.  
Hs578T and SUM149 breast cancer cells lines were found to express 
multiple markers of CSCs  (ALDH activity, expression of CSC-associated genes), 
and four functional CSC markers (tumorsphere formation, accelerated migration 
in a scratch wound model, chemotherapeutic resistance, and tumor formation in 
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xenografts). The potential for the AHR to directly interact with the promoter of 
Sox2, a master regulator of CSC (and normal tissue-specific stem cell) self-
renewal and differentiation, and Runx1 was a particular area of focus. Finally, the 
effects of multiple AHR ligands on expression of CSC markers were studied.  Our 
results show that the AHR is involved in phenotypic, genomic, and functional 
CSC markers, strongly implicating an important role for the AHR in CSC biology, 
encouraging development of AHR-targeted therapeutics, and raising the 
possibility that environmental AHR ligands may drive CSC development and/or 
function. 
Defining of Hypothesis and Experimental Aims 
Here, we hypothesize that the AHR is a key player in BSCS biology 
through the control of multiple phenotypic and functional characteristics, 
including: ALDH1 activity and expression, tumorsphere formation, expression of 
stem cell- and invasion/migration associated markers, cell migration, 
chemotherapeutic resistance, and in vivo tumor formation. We have defined 
three major aims to elucidate the role of the AHR in molecular and function 
characteristics of BCSC biology. Our first aim is to define the functional relevance 
of AHR signaling to BCSC biology in a TNBC model and inflammatory breast 
cancer (IBC) model. Our second aim is to determine the mechanism by which 
AHR modulation affects BCSC population dynamics. Our third aim is to define 
the functional relevance of AHR signaling in BCSC biology in an in vivo model.  
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AIM ONE 
Our first aim is to define the functional relevance of AHR signaling to 
BCSC biology in a TNBC model and inflammatory breast cancer (IBC) model. 
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AIM ONE METHODS  
Chemicals 
DMSO, β-Naphthoflavone (β-NF), 7,12-Dimethylbenz[a]anthracene 
(DMBA), 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), paclitaxel, doxorubicin and 
doxycycline were obtained from Sigma-Aldrich (St. Louis, MO). 6-
Formylindolo(3,2-b)carbazole (FICZ) was obtained from Santa Cruz 
Biotechnology (Dallas, TX). CH223191 and CB7993113 were provided by Dr. M. 
Pollastri (Northeastern University). 
Cell Line Acquisition, Cell Culture, and Media  
Hs578T cells were purchased from and cultured according to ATCC 
recommendations (ATCC, Manassas, VA). Briefly, Hs578T cells were maintained 
in DMEM Medium (Mediatech, Herndon, VA) containing 5% FBS (Sigma-
Aldrich), 0.0194 M D-Glucose (Sigma-Aldrich), 2 mM L-glutamine (Mediatech), 
100 I.U. penicillin/100 µg/ml streptomycin (Mediatech), 10 µg/ml insulin (Sigma-
Aldrich), and 5 µg/ml Plasmocin (Invivogen, San Diego, CA), at 37°C with 5% 
CO2.  
MCF-10F cells were purchased from and cultured according to ATCC 
recommendations (ATCC, Manassas, VA). Briefly, MCF-10F cells were 
maintained in DMEM/F12 Medium (Mediatech, Herndon, VA) containing 5% 
Horse Serum (Sigma-Aldrich), 2 mM L-glutamine (Mediatech), 100 I.U. 
penicillin/100 µg/ml streptomycin (Mediatech), 10 µg/ml insulin (Sigma-Aldrich), 
0.5 µg/ml hydrocortisone (Sigma-Aldrich), 20 ng/mL recombinant human 
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epidermal growth factor (Gibco, Carmillo, CA), and 5 µg/ml Plasmocin 
(Invivogen, San Diego, CA), at 37°C with 5% CO2. 
MCF-10A cells were purchased from and cultured according to ATCC 
recommendations (ATCC, Manassas, VA). Briefly, MCF-10A cells were 
maintained in DMEM Medium (Mediatech, Herndon, VA) containing 5% Horse 
Serum (Sigma-Aldrich), 2 mM L-glutamine (Mediatech), 100 I.U. penicillin/100 
µg/ml streptomycin (Mediatech), 10 µg/ml insulin (Sigma-Aldrich), 0.5 µg/ml 
hydrocortisone (Sigma-Aldrich), 20 ng/mL recombinant human epidermal growth 
factor (Gibco, Carmillo, CA), 100n ng/mL cholera toxin (Sigma)-Aldrich, and 5 
µg/ml Plasmocin (Invivogen, San Diego, CA), at 37°C with 5% CO2. 
SUM149 cells were a generous gift from Dr. Stephen Ethier (Wayne State 
University, Detroit, MI). SUM149 cells were maintained in F-12 Medium 
(Mediatech, Herndon, VA) containing 5% FBS (Sigma-Aldrich), 0.5 µg/ml 
hydrocortisone (Sigma-Aldrich), 2 mM L-glutamine (Mediatech), 100 I.U. 
penicillin/100 µg/ml streptomycin (Mediatech), 10 µg/ml insulin (Sigma-Aldrich), 
and 5 µg/ml Plasmocin (Invivogen, San Diego, CA), at 37°C with 5% CO2.  
Inducible, Stable Ahr-specific shRNA Cells  
Doxycycline (dox)-inducible TurboRFP-shAhr TRIPZ lentiviral vector 
(Open Biosystems, Huntsville, AL) was used to make viral transduction particles. 
Hs578T and SUM149 cells were transduced at optimal MOIs of 25 and 50, 
respectively, in medium containing hexadimethyrine bromide (8 µM polybrene; 
Sigma-Aldrich). Transduced cells were maintained in 1.5 µg/ml puromycin 
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(Invitrogen, Grand Island, NY). RFP expression was maximal 48 hours after dox 
treatment (1.5 µg/ml) of transduced cells.  
ALDEFLUOR™ Staining 
Cells were dosed with 0.5 µM FICZ, 1 µM  β-NF, 10 µM CH223191, 10 µM 
CB7993113, 1 nM TCDD, 1 µM DMBA, 1.5 µg/mL dox and/or vehicle (0.1% 
DMSO) every 24 hours. After 48 hours, ALDEFLUOR™ assays were performed 
according to the manufacturer’s instructions (StemCell Technologies, Vancouver, 
Canada). Cells (106 cells/ml) were treated with 5 µl/ml ALDEFLUOR substrate. 
Negative controls were treated with 50 mmol/L diethylaminobenzaldehyde 
(DEAB), an ALDH-specific inhibitor. Samples were incubated for 35 minutes at 
37° C, and propidium iodine (PI) added (1.5 mg/ml) to quantify viability (PI was 
not used on TurboRFP-shAhr transduced cells due to overlapping emissions). 
Cells were assayed with an LSRII flow cytometer (Becton Dickinson Biosciences, 
San Jose, CA) using DEAB controls for gating. Data were analyzed using FlowJo 
Software (FlowJo, Ashland, OR). ALDHhigh and ALDHlow cells were sorted on a 
MoFlo Legacy (Beckman Coulter, Indianapolis, IN). 
Tumorsphere formation 
Cells were treated as above. After 48 hours, cells were harvested, dosed, 
and 3 x 103 cells plated in complete MammoCult Medium (STEMCELL 
Technologies) containing 0.5 µM g/ml hydrocortisone, 2 mM L-glutamine, 100 
I.U. penicillin/100 µM g/ml streptomycin, and 1% methylcellulose (Sigma Aldrich) 
on ultra-low adherent 24-well plates (Corning Inc.). Colonies were quantified with 
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a Celigo S Imaging Cytometer (Brooks Automation, Chelmsford, MA) after 8 
days. For secondary sphere formation, tumorspheres were mechanically and 
enzymatically dissociated into a single cell suspension, re-plated and imaged as 
above. 
RT-qPCR  
 mRNA was extracted using RNeasy® Plus Mini Kit (Qiagen, Valencia, CA) 
and cDNA prepared using the GoScript™ Reverse Transcription System 
(Promega, Madison, WI) with a 1:1 mixture of random and Oligo (dT)15 primers. 
All RT-qPCR reactions were performed using the GoTaq® RT-qPCR Master Mix 
System (Promega). Validated primers were purchased from Qiagen Inc. 
(Valencia, CA): human Cyp1b1 - QT00209496, Twist1 – QT00011956, Snai1 – 
QT00010010, Snai2 – QT00044128, VIM – QT00095795, Twist2 – QT02454004, 
FN1 – QT00038024, Notch1 – QT01005109, Notch2 – QT00072212,  Aldh1a1 – 
QT00013286, Pou5f1 – QT00210840, Sox2 – QT00237601, Nanog – 
QT01844808, DPPA3 – QT01667197, MSI1 – QT00025389, Human Bmi1 – 
QT00052654, Tgfb1 – QT00000728, Runx1 – QT00026712, Ahr – QT02422938, 
and Gapdh – QT01192646. RT-qPCR reactions were performed using a 7900HT 
Fast Real-Time PCR instrument (Applied Biosystems, Carlsbad, CA), with hot-
start activation at 95° C for 2 min, 40 cycles of denaturation (95° C for 15 sec) 
and annealing/extension (55° C for 60 sec). Relative gene expression was 
determined using the Pfaffl method (Pfaffl, 2001) and the threshold value for 
Gapdh mRNA was used for normalization.  
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Transient Transfection 
Hs578T or SUM149 cells were co-transfected with the pGudluc reporter 
plasmid (0.5 µg) (generously provided by Dr. M.  Denison, UC, Davis) and CMV-
green (0.1 µg) using TransIT-2020 transfection reagent (Mirus, Madison, WI). 
Transfection medium was replaced after 24 hours. Cells were then left untreated 
or dosed with vehicle (DMSO, 0.1% final concentration) or CH223191 (10 µM). 
For reporter activity assays, cells were lysed after 24 hours in Glo Lysis Buffer 
(Promega, San Luis Obispo, CA). Luciferase activity was determined with the 
Bright-Glo Luciferase System according to the manufacturer’s instructions 
(Promega). Luminescence and fluorescence were determined using a Synergy2 
multifunction plate reader (Bio-Tek, Winooski, VT).  
Scratch-Wound Assay 
ALDHhigh and ALDHlow cells were sorted and grown to confluence in 12-
well plates.  Unsorted cells were grown to confluence in 6-well plates. A p200 
pipet tip was used to make an “X” in each well. Plates were washed three times 
with PBS to remove non-adherent cells.  Fresh media was added and cells 
treated with vehicle, 10 µM CH223191, 10 µM CB79930998, 1 nM TCDD, or 0.5 
µM FICZ. Media was changed and cells were re-dosed at 24 and 48 hours. Cells 
were imaged at the time of scratching/wounding, and every 24 hours post 
scratching/wounding. TScratch software (Tobias Gebäck and Martin Schulz, ETH 
Zürich) was used to quantify the closure of the scratch over time.  
CFSE Staining 
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 SUM149 cells were stained with the CellTraceTM CFSE Cell Proliferation 
Kit (Life Technologies, Carlsbad, CA) according to the manufacturer’s 
instructions, prior to plating of the scratch assay as described above. Cells were 
harvested 48 hours after scratching and read on a LSRII flow cytometer (Becton 
Dickinson Biosciences, San Jose, CA). Data were analyzed using FlowJo 
Software (FlowJo, Ashland, OR). 
Statistical analyses 
Statistical analyses were performed with StatPlus (Alexandria, VA) unless 
otherwise noted. Data are presented as means + SEMs where applicable. One-
way analyses of variants (ANOVAs) (simple) were used to determine 
significance. For experiments measuring relative fold-changes in gene 
expression (determined using the Pfaffl method (Pfaffl, 2001)  with Gapdh mRNA 
used for normalization), statistical analyses were performed using SAS v9.3. For 
comparisons of fold-change in vehicle-treated ALDHhigh versus vehicle-treated 
ALDHlow, and FICZ-treated ALDHlow versus vehicle-treated ALDHlow cells, Gapdh-
normalized expression levels were normalized to expression levels in vehicle-
treated ALDHlow cells. For comparisons of fold-change with FICZ-treated 
ALDHhigh versus vehicle-treated ALDHhigh cells, Gapdh-normalized expression 
levels were normalized to expression levels in vehicle-treated ALDHhigh cells. 
Statistical significance was determined with the Wilcoxon rank sum test.  
All graphs were created using Prism 6 (GraphPad Software, La Jolla, CA). 
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AIM ONE RESULTS 
Ahr expression is elevated in ALDH1high TNBC and IBC cells 
Work from several laboratories indicates a role for the AHR in tissue-
specific stem cell development (Gasiewicz, et al., 2014, Ko, et al., 2014, Singh, 
et al., 2014, Singh, et al., 2011, Wang, Qin, et al., 2013) suggesting a general 
role for the AHR in stem cell biology. We, as well as others, have demonstrated 
that the AHR is highly expressed and constitutively active in breast cancers and 
that AHR activity correlates with tumor aggressiveness (Currier, et al., 2005, Hall, 
et al., 2010, Murray, et al., 2005, Schlezinger, et al., 2006, Trombino, et al., 
2000). Since CSCs contribute to tumor progression, we postulated that the AHR 
plays a role in the development of breast cancer cells with stem cell 
characteristics.  
One readily assessed marker of “stem-ness” is the elevated expression of 
ALDH1, an enzyme implicated in chemoresistance (Croker and Allan, 2011, 
Economopoulou, et al., 2012).  A fluorescence-based ALDH1 enzyme activity 
assay (Charafe-Jauffret, et al., 2010, Charafe-Jauffret, et al., 2009, Croker and 
Allan, 2011, Croker, et al., 2009, Ginestier, et al., 2007) was used to quantify 
ALDH1 activity in TNBC Hs578T cells which express relatively high levels of 
transcriptionally active AHR (Yang, Xinhai, et al., 2008). Cells were sorted by 
flow cytometry into ALDH1high and ALDH1low subsets based on gating after 
treatment with diethylamino-benzaldehyde (DEAB), an ALDH inhibitor used for 
gating (Figure 1). Approximately 5% of Hs578T cells expressed a high level of 
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ALDH1 activity (“ALDHhigh”) (Figure 1, right panel), a result consistent with 
previous studies of CSCs (Charafe-Jauffret, et al., 2009). IBC is a particularly 
aggressive form of cancer characterized by a ~50% survival rate at 2 years 
(Gonzalez-Angulo, et al., 2007). Approximately 10.4% of SUM149 cells, an IBC 
cell line, expressed high levels of ALDH1 activity (Aim 1, Figure 10). To 
determine if the Ahr and an AHR target gene, Cyp1b1, are more highly 
expressed in CSCs, Ahr and Cyp1b1 mRNA levels were quantified by RT-qPCR. 
Ahr and Cyp1b1 mRNA levels were significantly higher in ALDHhigh cells than 
ALDHlow cells (p<0.05-0.005) (Aim 1, Figure 2). Similarly, in SUM149 cells, 
ALDHhigh cells exhibited a significantly higher level of Ahr, Cyp1b1, and Aldh1a1 
mRNA expression than ALDHlow cells (p<0.05-0.005) (Figure 3). 
To determine if elevated Ahr and Cyp1b1 expression in ALDH1high cells 
reflects a role for the AHR in maintaining stem cell properties, and if 
environmental AHR ligands have the potential to increase these properties, AHR 
expression or activity was modulated. AHR expression or activity was modulated 
with a doxycycline (dox)-inducible Ahr-specific shRNA (shAhr), AHR inhibitors 
(CH223191 and CB7993113) (Choi, et al., 2011, Kim, SH, et al., 2006, Parks, et 
al., 2014), or four AHR agonists: 1) 6-formylindolo[3,2-b]carbazole (FICZ), a high 
affinity AHR ligand, tryptophan photo-metabolite and potential endogenous ligand 
(Jönsson, et al., 2009), 2)  β-NF, a flavone with moderate affinity for the AHR,  3) 
2,3,7,8-tetrachlorodibenzo(p)dioxin (TCDD), a high affinity, persistent 
environmental AHR ligand and “gold standard” AHR ligand, and 4) 7,12 
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dimethylbenzanthracene (DMBA), a readily metabolizable polycyclic aromatic 
hydrocarbon.  
Dox-induced shAhr or the AHR-specific inhibitor CH223191 significantly 
reduced (p<0.01-0.0001) Ahr expression and AHR-dependent (pGudLuc) 
reporter activity respectively (Aim 1, Figure 4), significantly decreased (p<0.05-
0.0005) the percentage of ALDHhigh cells (Aim 1, Figure 5), and reduced overall 
expression of ALDH1 activity in the entire population (Aim 1, Figure 6). These 
data suggest that constitutively active AHR maintains baseline ALDH1 levels. 
Conversely, FICZ,  β-NF, TCDD and DMBA significantly increased the 
percentage of ALDH1high cells and ALDH1 activity in the entire population 
(p<0.05-0.005) (Aim 1, Figure 5). In all cases, AHR agonist-induced increases 
were significantly inhibited by CH223191 (p<0.05-0.001) (Aim 1, Figure 5). 
Similar results were obtained with immortalized, but non-malignant triple negative 
MCF-10F and MCF-10A cells (Aim 1, Figure 7 and Figure 8, respectively). In 
SUM149 IBC cells, CH223191 or Ahr-specific shRNA significantly decreased 
AHR activity or expression greater than 60% (p<0.01-0.0001) (Aim 1, Figure 9), 
the percentage of ALDHhigh cells (p<0.05-0.0005) (Aim 1, Figure 10), and overall 
ALDH1 activity in the entire population (not shown). Conversely, FICZ, β-NF, 
TCDD and DMBA significantly increased the percentage of ALDHhigh cells 
(p<0.01-0.005) (Aim 1, Figure 10) and CH223191 treatment in tandem 
significantly reduced this increase (p<0.05-0.01) (Aim 1, Figure 10). 
Increasing AHR activity increases expression of CSC-related genes 
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To determine if several stem cell-associated genes are regulated by the 
AHR, Hs578T cells were treated for 48 hours with vehicle or FICZ, stained with 
ALDEFLUOR, and sorted into ALDHhigh and ALDHlow populations. As expected, 
vehicle-treated ALDHhigh cells produced higher levels of Aldh1a1, Ahr, and 
Cyp1b1 than vehicle-treated ALDHlow cells (p<0.005) (Aim 1, Figure 11). 
Additionally, ALDHhigh cells expressed significantly higher levels of Runx1, 
Notch1, Notch2, Sox2, Oct4, Bmi1, Nanog, and Dppa3 (p<0.05-0.005), with Msi1 
being the exception (Aim 1, Figure 11). As expected (see Aim 1, Figure 5), FICZ 
treatment increased Aldh1a1 and Cyp1b1 expression in both ALDHlow and 
ALDHhigh cells (p<0.05-0.01) (Figure 12, 13). FICZ treatment also increased 
expression of Runx1, Notch1, Notch2, Sox2, Oct4, Bmi1, Nanog, and Dppa3 in 
both cell subsets (p<0.05-0.005), again with Msi1 being the outlier (Aim 1, Figure 
12, 13). These results support the hypothesis that constitutively active and/or 
exogenous agonist-induced AHR up-regulates multiple stem cell-associated 
genes. Several of these genes express multiple consensus AHR binding sites 
(Aim 1, Table 1), suggesting that they may be directly regulated by the AHR.  
Increasing AHR activity increases expression of migration- and invasion-
associated genes 
CSCs are characterized as being more invasive than the bulk tumor 
population and having increased expression of migration- and invasion-
associated markers (Chaffer, et al., 2011, Croker and Allan, 2011, 
Economopoulou, et al., 2012, Gangopadhyay, et al., 2012, Mani, et al., 2008, 
  
38 
Raimondi, et al., 2011, Scheel and Weinberg, 2012). To determine if the increase 
in stem cell markers described above correlates with an increase in markers of 
migration and invasion, Hs578T cells were treated with vehicle or FICZ for 48 
hours, sorted for ALDHhigh and ALDHlow cells, and evaluated for expression of 
seven genes associated with increased tumor migration and/or invasion. As seen 
for stem cell markers (Aim 1, Figure 11-13), ALDHhigh cells expressed 
significantly higher levels (p<0.005-0.0005) of Snai1, Twist1, Twist2, and Vim 
than ALDHlow cells, with Twist2 showing the greatest fold-change (Aim 1, Figure 
14). Although Snai2 and Fn1 tended to be higher in ALDHhigh cells, neither was 
statistically significant in nine experiments. These data are consistent with the 
CSC properties of ALDHhigh cells. AHR hyper-activation with FICZ significantly 
(p<0.05-0.0005) increased Snai1, Twist1, Twist2, and Vim expression in both 
ALDHhigh and ALDHlow cells (Aim 1, Figure 15, 16) and Tgfb1 expression was 
marginally increased in FICZ-treated ALDHlow cells (Aim 1, Figure 16).  
Generalization of the correlation between Ahr or Cyp1b1 and CSC- and 
invasion/migration-associated genes 
The experiments described above confirm that AHR hyper-activation with 
FICZ induces both CSC-associated and migration/invasion-associated genes in 
an AHR-dependent fashion in Hs578T cells.  If these associations are 
generalizable, then it would be predicted that Ahr expression and expression of 
Cyp1b1, a marker for AHR activity, would correlate, in multiple breast cancer cell 
lines, with expression of the CSC- and migration/invasion-associated gene sets 
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identified in Hs578T cells. For such an analysis, we used microarray/RNA-seq 
data compiled by the Broad Institute on 79 primary human breast cancer cell 
lines, i.e., the Cancer Cell Line Encyclopedia (CCLE) (Barretina, et al., 2012). 
Use of Cyp1b1 as a marker for AHR activity in this context is supported by: 1) our 
findings (Yang, X., et al., 2008), and those of others (Shehin, et al., 2000), 
demonstrating that baseline Cyp1b1 mRNA levels are maintained in part by 
constitutively active AHR in human breast cancer cell lines and 2) the 
observation that, of all breast cancer cell lines in the CCLE, the nearest neighbor 
to Ahr of >20,000 gene probes is Cyp1b1 (p=0.0019). (This is not to say that 
there are no other factors regulating Cyp1b1 expression (Shehin, et al., 2000)).  
Gene set enrichment analyses (GSEA) were performed with the aim of 
testing whether the genes listed in Aim 1, Table 1 are significantly and 
coordinately correlated with Ahr or Cyp1b1 expression. (GSEA is an approach to 
testing for the co-regulation of Ahr with its putative target gene set that is 
statistically more powerful than testing each target gene individually). Indeed, Ahr 
expression was significantly correlated (false discovery rate=0.025) with the 
putative AHR target gene set shown in Aim 1, Table 1 (Figure 17A). GSEA of 
Cyp1b1 co-regulation with the set of putative AHR gene targets tests the 
hypothesis that expression of these genes, as a set, is non-randomly linked to 
Cyp1b1 expression, as a marker for AHR activity. As predicted, there was a 
significant correlation between Cyp1b1 and the expression of the putative AHR 
target gene set from Aim 1, Table 1 (FDR=0.021) (Aim 1, Figure 17B).  
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Interestingly, the “outlier” with a negative correlation score for both the Ahr and 
Cy1b1 analyses (Aim 1, Figure 17A and 17B, red arrow), is Msi1, the one stem 
cell-associated gene that did not increase in ALDHhigh cells or following AHR 
hyper-activation (Aim 1, Figure 17).  
 A similar GSEA analysis was performed using transcriptomic data from 
977 primary human breast cancers catalogued in the Cancer Genome Atlas 
(TCGA) database (Ma and Ellis, 2013) and 995 primary human breast cancers in 
the Curtis database (Curtis, et al., 2012).  As shown for cell lines in the CCLE, 
there was a significant association (FDR=0.047) between Ahr expression and the 
gene set listed in Aim 1, Table 1 (Aim 1, Figure 18A). A stronger association 
(FDR=0.0001) was seen between Cyp1b1 expression and expression of the 
putative AHR target gene set (Aim 1, Figure 18B). As with the CCLE database, 
Msi1 was not correlated with either Ahr or Cyp1b1 in the TCGA database (Red 
arrows, Figure 18A, 18B). Similar data were obtained using the Curtis dataset 
(not shown). Collectively, data mined from three large breast cancer databases 
(CCLE, TCGA, and Curtis) show a significant and generalizable association 
between the Ahr and AHR activity (Cyp1b1 expression) and CSC- and 
migration/invasion-associated gene sets (Aim 1, Table 1). These findings are 
consistent with the regulation of these genes by a constitutively active (i.e., 
endogenous AHR ligand-activated) AHR.   
Modulating AHR activity alters cell migration 
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As a functional readout of migration, the effects of AHR modulation on the 
ability of SUM149 cells to migrate in a scratch-wound assay were determined. As 
expected, vehicle-treated ALDHhigh cells “repaired” the wound significantly faster 
than vehicle-treated ALDHlow cells (Aim 1, Figure 15) (p<0.05 at 48 hours). 
Furthermore, wound repair with both subpopulations was significantly inhibited by 
CH223191 (Aim 1, Figure 19) (p<0.05-0.0005). Similar data were obtained with 
unsorted Hs578T and SUM149 cells and with another AHR inhibitor, CB7993113 
(Aim 1, Figure 20) (Parks, et al., 2014). In addition, both 0.5 µM FICZ and 1 nM 
TCDD significantly accelerated migration of unsorted, ALDHlow, and ALDHhigh 
SUM149 subsets (Aim 1, Figure 22). A significant increase in migration rate was 
only seen for ALDHhigh cells following a 48-hour treatment with a lower TCDD 
dose (0.2 nM, not shown). No significant changes in cell divisions were observed 
between treatment groups over this 48-hour period as assessed by CFSE 
staining quantified by flow cytometry (Aim 1, Figure 21). 
Decreasing AHR activity decreases tumorsphere formation 
CSCs can form tumorspheres and produce progenitor cells over several 
passages in ultralow adherence conditions (Charafe-Jauffret, et al., 2009, Dontu 
and Wicha, 2005, Fillmore and Kuperwasser, 2008, Li, et al., 2008, Ponti, et al., 
2006). To determine if the AHR contributes to this functional readout of CSCs, 
Hs578T cells were cultured in Mammocult media under ultra-low adherence 
conditions and AHR activity and expression were modulated with CH223191 or 
with dox-inducible shAhr. Both the size and total number of tumorspheres were 
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significantly reduced (p<0.05-0.005) by CH223191 or dox-induced shAhr in 
primary, secondary (Aim 1, Figure 23A and 23B), tertiary, and quaternary (not 
shown) cultures. No effect on cell viability (trypan blue exclusion) was seen (the 
percent viability is indicated in the upper right corner of each image in Figure 
23A). Similar results were obtained with CB7993113 (not shown). These results 
suggest that the AHR regulates tumorsphere formation and the ability of CSCs to 
(asymmetrically) divide and/or differentiate into progenitor cells in low-adherence, 
selective conditions. The results also suggest that the AHR controls the ability of 
progenitor cells to divide. Similar results were seen with SUM149 IBC cells after 
treatment with CH223191 (p<0.05-0.01) (Aim 1, Figure 24A and 24B). MCF-10A, 
a non-malignant TNBC line, was able to form primary “spheres” that significantly 
responded to CH223191 treatment (p<0.01), however, the total number of 
spheres decreased following serial passages (Aim 1, Figure 25).  
Decreasing AHR activity decreases chemoresistance, a hallmark of CSCs 
Chemoresistance is another widely studied functional CSC marker 
(Clevers, 2011, Croker and Allan, 2011, Economopoulou, et al., 2012, Fillmore 
and Kuperwasser, 2008, Gangopadhyay, et al., 2012, Li, et al., 2008, Qiu, et al., 
2013). To determine if the AHR influences chemoresistance, ALDHhigh and 
ALDHlow Hs578T cells were treated with titrated doses of adriamycin or 
paclitaxel, chemotherapeutics with distinct mechanisms of action, with or without 
CH223191. Cell viability was assayed after 24 hours. As expected of CSC, 
ALDHhigh cells were more resistant to the chemotherapeutics than ALDHlow cells 
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(see EC50s in Aim 1, Table 2). CH223191 had no effect on viability (not shown). 
However, CH223191 significantly (p<0.05-p<0.005) increased sensitivity to both 
adriamycin and paclitaxel in both ALDHlow and ALDHhigh cells (Aim 1, Figure 26 
and Figure 27). The half maximal effective concentration (EC50) of adriamycin-
treated ALDHhigh cells (EC50=1.99 µM) was three times greater than that of 
adriamycin + CH223191-treated cells (EC50=0.60 µM) (Aim 1, Figure 26B and 
Aim 1, Table 2).  
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AIM ONE DISCUSSION 
Accumulating data suggest that the AHR plays an important role in breast 
cancer in general, and in progression to end-stage metastasis in particular. For 
example, the Ahr is hyper-expressed and transcriptionally active in most TNBC 
and IBC cell lines. Ahr expression also has been found to be associated with 
tumor invasion (Goode, et al., 2013, Kim, et al., 2000, Schlezinger, et al., 2006, 
Yang, X., et al., 2008). Additionally, when probing mRNA expression in Hs578T 
and SUM149 populations sorted on the basis of ALDH1 activity, Ahr and Cyp1b1 
expression were significantly increased (Aim 1, Figure 1 and 2).  Elevated 
ALDH1 activity is a functional marker for CSCs, directly implicating the AHR in 
CSC biology. The data presented here strongly suggest that the AHR may drive 
late stage tumorigenesis through induction and/or maintenance of CSCs.  
The involvement of the AHR in CSC biology is suggested by its emerging 
role in normal tissue-specific stem cell development. The AHR, presumably 
activated by endogenous ligand(s), helps maintain hematopoietic stem cell 
(HSC) self-renewal, blocks HSC differentiation (Boitano, et al., 2010, Singh, et 
al., 2014, Singh, et al., 2011), and drives bipotential blood stem cell 
differentiation at later stages of hematopoiesis (Smith, et al., 2013). AHR 
repression in embryonic stem cells likely maintains pluripotency, and the AHR 
controls embryonic stem cell differentiation into cardiomyocytes (Wang, Q., et al., 
2013). Data presented here extend these studies by demonstrating that the AHR 
is involved in the phenotype (ALDH1 activity and Aldh1a1 expression), genomics 
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(up-regulation of stem cell- and migration/invasion-associated genes), and 
function (migration, chemoresistance, tumorigenicity) of CSCs.  Elevated Aldh1 
expression characterizes CSCs and is associated with increased expression of 
chemoresistance proteins, increased tumor cell invasion, higher tumor grade, 
and poor survival in breast cancer patients (Charafe-Jauffret, et al., 2010, Croker 
and Allan, 2011, Economopoulou, et al., 2012, Mani, et al., 2008, Tanei, et al., 
2009).  Indeed, in our hands, ALDHhigh cells exhibited elevated expression of 
stem cell- and migration/invasion-associated genes (Aim 1 Figures 11-17), faster 
cell migration (Aim 1 Figures 15 and 17) and increased chemoresistance (Aim 1 
Figures 21 and 22). 
Elevated ALDH1 expression and activity is a crucial characteristic of 
BCSCs, but what is controlling ALDH1 expression and activity has not been 
widely studied. Here, we found that treating SUM149 or Hs578T cells with AHR 
agonists such as FICZ, TCDD, β-NF or DMBA led to an increase in ALDH1 
activity within the entire population. Treatment with CH223191, an AHR 
antagonist, or treatment with CH223191 and an agonist in combination led to a 
decrease in ALDH1 activity in the entire population (Aim 1, Figures 5 and 10). 
This shows, in part, that the AHR is regulating a key marker of CSCs, ALDH1 
activity, implicating the AHR as a key player in CSC biology in malignant TNBCs 
and IBCs. Similar results were seen with MCF-10F and MCF-10A cell lines, 
which are non-malignant breast cancer cells lines. ALDH1 is an important marker 
of CSCs that is widely studied as it is involved in differentiation of stem cells by 
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oxidizing retinol to retinoic acid (Chute, et al., 2006).  Additionally, ALDH1 is also 
believed to play an important role in chemoresistance of beast cancer cells 
(Croker, et al., 2009, Raha, et al., 2014).    
  Chemotherapeutic resistance is a key attribute of CSCs that allows the 
CSCs to survive and proliferate following chemotherapy.  The surviving CSCs 
can then lead to breast cancer recurrence and metastasis. Our data show that 
targeting the AHR with an AHR antagonist, CH223191, in conjunction with a 
chemotherapeutic makes the chemotherapeutic more effective in killing both 
ALDHhigh and ALDHlow cell populations (Aim 1 Figures 22 and 23, see Aim 1, 
Table 2). We hypothesize that this may be due to the fact that AHR antagonism 
is decreasing ALDH1 activity and pushing cells towards an ALDHlow phenotype 
(Aim 1, Figure 5). ALDHhigh cells are protected from accumulation of reactive 
oxygen species (ROS), which can be toxic to cells. High levels of ROS can lead 
to DNA damage and cell apoptosis. Cells with high levels of ALDH activity are 
able to detoxify toxic aldehyde intermediates, prevent the build-up of ROS, and 
increase their survival (Raha, et al., 2014). If treating with an AHR antagonist 
decreases ALDH activity, then it is hypothesized that cells will be more sensitive 
to chemotherapeutics and cell death.  
  Another potential way in which the AHR is modulating chemoresistance is 
through control of the breast cancer resistance protein (BCRP, also known as 
ABCG2). BCRP is an ATP-binding cassette transporter, which is able to aid in 
chemotherapeutic resistance by pumping chemotherapeutics out of cells. This 
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prevents the buildup of chemotherapeutics in cells, which can lead to cell death 
(Tan, et al., 2010). A previous study has shown that AHR antagonism leads to a 
decrease in BCRP expression and AHR agonism leads to an increase in BCRP 
expression (Tan, et al., 2010). Additionally, ChIP assays have shown that the 
AHR directly binds to the promoter of the BCRP (Tan, et al., 2010). Both ALDHlow 
and bulk tumor cells are highly responsive to treatment with chemotherapeutics 
(Aim 1, Figure 26 and 27). Increased overall cell death is seen at lower 
chemotherapeutic doses when cells are treated with an AHR antagonist at the 
same time (Aim 1, Figure 26 and 27). Treating patients at lower 
chemotherapeutic doses could potentially lead to a decrease in the side effects 
associated with cancer treatment. This novel approach of using both a traditional 
therapeutic with an AHR antagonist also could lead to more effective targeting of 
CSCs, as well as overall prevention of cancer recurrence and metastasis. Further 
research needs to be performed to determine the exact mechanism of how 
decreasing AHR activity is leading cells to be more sensitive to chemotherapy. 
  Cell populations sorted on the basis of ALDH1A1 activity led to two distinct 
populations, ALDHhigh and ALDHlow. Based on literature reviews, and the number 
and location of AHREs in the promoter of the genes from Aim 1, Table 1, genes 
that control traditional stem cells, CSCs, and invasion/migration were probed by 
RT-qPCR in the ALDH sorted populations. As a first pass to ensure that these 
genes were in fact correlated to CSCs, we confirmed that ALDHhigh cells had 
elevated mRNA expression of the markers from Aim 1, Table 1 (Aim 1, Figures 
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11 and 14). Then, we further probed the relationship of AHR to these genes of 
interest by AHR hyper-activation with FICZ. AHR hyper-activation led to 
increased expression of Aldh1a1 and stem cell-associated genes, demonstrating 
a causal relationship between AHR activity and gene expression in both the 
ALDHlow and the ALDHhigh populations (Aim 1, Figures 12 and 13, respectively). 
These genes have been implicated in generating both tissue specific stem cells 
and CSCs, and based on our data, are directly correlated with AHR expression 
and activity.  
  The Notch signaling pathway is critical to symmetric and asymmetric cell 
division, and stem cell differentiation in embryonic and adult stem cells (Bolós, et 
al., 2009, Simmons, et al., 2012). NOTCH1 and NOTCH2 also are potential 
therapeutic targets for TNBCs (Hombach-Klonisch, et al., 2008, Qiu, et al., 2013). 
Bmi1 is required for the maintenance of somatic stem cells through repression of 
cellular senescence and cell death (Park, et al., 2004). Additionally, BMI1 is 
involved in the control of CSC growth, chemoresistance and tumorsphere 
formation (Paranjape, et al.). Stella is involved in maintenance of gene-specific 
DNA methylation in the early embryo, and is a marker for some CSC types 
(Ezeh, et al., 2005). SOX2, OCT4 and NANOG are traditional embryonic stem 
cell markers used to reprogram cells to a pluripotent state, and are expressed at 
elevated levels in CSCs (Chiou, et al., 2010, Ezeh, et al., 2005, Leis, et al., 2011, 
Takahashi and Yamanaka, 2006). Our data show that AHR expression and 
activity is correlated with the expression of these key genes, implicating the AHR 
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in the control of many key stem cell controllers/regulators. 
  Our data also suggest that the AHR plays a key role in regulating CSC 
migration and invasion. Snail, Slug, Twist1, Twist2, Tgfb1 and Fibronectin (Fn1) 
are all involved in invasion and cell migration (Battula, et al., 2010, Mani, et al., 
2008, Morel, et al., 2008). The majority of these makers are found to be 
significantly up-regulated in ALDHhigh versus ALDHlow cells (Aim 1, Figure 14). 
Additionally, FICZ-treated ALDHlow and ALDHhigh cells had significantly higher 
levels of mRNA expression than compared to vehicle-treated ALDHlow and 
ALDHhigh cells, respectively (Aim 1, Figures 15 and 16). As would be predicted 
from these results, AHR inhibition in sorted SUM149 cells slows (Aim 1, Figure 
19) and AHR hyper-activation accelerates (Aim 1, Figure 21) cell migration in the 
scratch-wound assay. Similar results were seen in unsorted Hs578T and 
SUM149 cells (Aim 1, Figure 20). These data implicate the AHR in control of cell 
invasion and migration, a key function and marker of CSCs. These data also 
strengthen the evidence that the AHR is a key player in CSC biology. Results 
from future Boyden-chamber and matrigel assays would help to further support 
these findings. It would also be beneficial to tag cells based on expression of a 
marker, such as a Sox2 or Slug reporter, to help further determine what genes 
are controlling BCSC biology. One could then monitor expression of those 
markers in cells that are migrating in a wound-healing assay and determine if the 
migrating cells express the markers of interest. We could then test to see if those 
cells expressing our genes of interest are ALDHhigh, are capable of forming 
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tumorspheres at a higher efficiency, and have increased levels of AHR 
expression and activity. 
  Importantly, these findings on AHR-regulated genes appear to be 
generalizable since strong correlations were seen between Ahr or Cyp1b1 and 
the stem cell- and migration/invasion-associated gene sets in silico. Our gene 
sets were coordinately and significantly expressed with Ahr or Cyp1b1 
expression in databases of 79 human breast cancer cell lines characterized in 
the CCLE and over 1850 primary human breast cancers catalogued in the TCGA 
and Curtis databases (Aim 1, Figures 17 and 18). These computational data are 
important to showing that our findings are generalizable to other cell lines and 
primary breast cancers. To support our in vitro findings and validate our in silico 
findings, we plan to perform similar experiments in primary breast cancer cells in 
vitro and show our findings are not cell-line specific and are generalizable.  
  Another functional marker of CSCs that we explored was tumorsphere 
formation. AHR inhibition or knockdown in either Hs578T or SUM149 cells 
significantly reduced the number and size of tumorspheres formed in low 
adherence conditions over several generations (Aim 1, Figures 23 and 24). The 
formation of these colonies is a function of asymmetric CSC division and 
production of progenitor cells, which constitute the majority of the cells in the 
spheres (Dontu and Wicha, 2005, Fillmore and Kuperwasser, 2008, Wicha, et al., 
2003). MCF-10A cells were able to form primary “spheres”, which were inhibited 
by CH223191 treatment. However, serial passage was not possible (Aim 1, 
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Figure 25). A key hallmark of CSCs is their ability to self-renew over several 
passages. The inability of MCF-10As to form spheres over several passages, 
may be due to the fact that MCF-10A cells are a non-malignant cell line. Our 
findings have shown that non-malignant cell lines form spheres but do not 
contain a CSC population that is capable of serial tumorsphere passage, perhaps 
because they are non-malignant (Fillmore and Kuperwasser, 2008, Keller, et al., 
2010). These findings support the notion that cancer stem cells are the true 
aggressors in cancers, and that more aggressive, malignant cell lines will have 
higher percentage of ALDHhigh cells with a greater ability to metastasize and self-
renew indefinitely.  
  Treatment with an AHR antagonist inhibits sphere formation, which leads 
to the hypothesis the AHR controls the asymmetric differentiation of CSCs and/or 
the growth of their progenitors.  Treatment of Hs578T and SUM149 cells with an 
AHR agonist did not significantly increase tumorsphere formation, nor did it 
decrease tumorsphere formation as seen previously (Prud'homme, et al., 2010, 
Zhao, et al., 2012). The lack of an increase in tumorsphere formation after 
agonist treatment could be due to many different factors. It is possible that the 
AHR is not controlling the expression of genes that are required for tumorsphere 
formation to occur in non-CSCs. The increase in expression of stem cell- and 
invasion/migration-associated genes is not sufficient to increase tumorsphere 
formation. It should be noted that tumorsphere formation and ALDH activity 
selection do not identify the exact same stem cell population, and are measuring 
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different functional markers of BCSCs (Ginestier, et al., 2007). Therefore, both 
assays should be used to study the different functional characteristics of CSCs. 
Past studies have shown that ALDHlow cells do not form tumorspheres, where 
around 10% of ALDHhigh cells were found to form tumorspheres (Ginestier, et al., 
2007). These findings begin to help to explain why agonist treatments did 
increase ALDH activity, while agonist treatments did not increase tumorsphere 
formation. The development of better in vitro systems to study, identify, and 
culture BCSCs is extremely important in helping to tease out the complex 
pathways that control BCSCs and to better study the role of the AHR in BCSC 
biology. 
 The role of the AHR in tissue-specific stem cell signaling is widely studied, 
however the role of the AHR in BCSC signaling is a novel field of study that 
needs to be further explored. Collectively, these results strongly implicate a role 
of the AHR in BCSC biology. Additionally, the implication that treating patients 
with lower doses of chemotherapeutics by co-treating with AHR inhibitors could 
potentially increase their quality of life tremendously. Future studies to further 
explore the role of the AHR in chemotherapeutic resistance, including in vivo 
modeling, may help to solidify these findings and determine the mechanism in 
which the AHR is controlling chemoresistance. Furthermore, an in-depth analysis 
of the genes listed in Aim 1, Table 1 will need to be performed to determine 
which genes are important to BCSC development and function, where the gene 
pathways overlap, and exactly how AHR signaling is controlling expression of 
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these markers. Specifically, Sox2 and Runx1 are two potential genes involved in 
BCSC biology that we have identified as being regulated by the AHR.  
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AIM ONE TABLES 
Aim 1, Table 1: Consensus AHREs in human stem cell-associated and 
migration- and invasion-associated gene promoters.  
Consensus AHR response elements (AHREs) were searched up to 3,000 
bp upstream of the transcription start site using the Transcriptional Regulatory 
Element Database (https://cb.utdallas.edu/cgi-
bin/TRED/tred.cgi?process=searchPromForm).  
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Aim 1, Table 1 
  
 Gene # of Consensus AHREs 
Standard Cyp1b1 8 
 
Stem Cell 
Markers 
 
 
 
 
 
Aldh1a1 0 
Sox2 7 
Nanog 10 
Dppa3 NA 
Pou5f1 3 
Bmi1 5 
Notch1 13 
Notch2 NA 
Runx1 13 
Msi1 7 
Invasion 
and 
Migration 
Markers 
 
 
Snai1 5 
Twist1 NA 
Vim 6 
Twist2 2 
Tgfb1 5 
Snai2 5 
Fn1 1 
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Aim 1, Table 2: The EC50s of two chemotherapeutics in the presence or 
absence of an AHR inhibitor, CH223191.  
EC50 values were calculated from the data presented in Aim 1, Figures 26 
and 27. CH223191 is an AHR inhibitor. 
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Aim 1, Table 2 
  
Cell Population Drug Treatment Chemotherapeutic EC50 (µM) 
ALDHlow Paclitaxel 0.81 
ALDHlow Paclitacel+CH 0.56 
ALDHhigh Paclitaxel 1.21 
ALDHhigh Paclitacel+CH 0.76 
ALDHlow Adriamycin 0.55 
ALDHlow Adriamycin+CH 0.20 
ALDHhigh Adriamycin 1.99 
ALDHhigh Adriamycin+CH 0.60 
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AIM ONE FIGURES 
Aim 1, Figure 1: ALDEFLUOR gating schematic.  
HER2-/ER-/PR- Hs578T cells were stained with ALDEFLUOR in the 
presence or absence of diethylaminobenzaldehyde (DEAB), a specific ALDH 
inhibitor, and ALDH activity (production of fluorescent substrate) quantified by 
flow cytometry. ALDHhigh and ALDHlow gates were set using dot plots from DEAB-
treated cells. Data are representative of >10 experiments.  
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Aim 1, Figure 1 
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Aim 1, Figure 2: Ahr and Cyp1b1 expression is increased in ALDHhigh 
Hs578T cells.  
Ahr and Cyp1b1 mRNA expression in sorted ALDHhigh and ALDHlow cells 
were quantified by RT-qPCR. Data from 4 independent experiments were 
analyzed using the Pfaffl method, normalized to the Gapdh signal, and presented 
as mean fold-change from ALDHlow + standard error. Asterisks indicate a 
significant increase in the mRNA fold change, *p<0.05, **p<0.005.  
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Aim 1, Figure 2 
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Aim 1, Figure 3: ALDHhigh SUM149 cells have increased expression of Ahr 
and Cyp1b1.  
A) Ahr, Cyp1b1 and Aldh1a1 mRNA expression in sorted ALDHhigh and 
ALDHlow SUM149 cells was quantified by RT-qPCR. Data from three independent 
experiments were analyzed using the Pfaffl method, normalized to the Gapdh 
signal, and presented as mean fold-change from ALDHlow + standard error. 
Asterisks indicate a significant increase in the mRNA fold change, *p<0.05, 
**p<0.01, ***p<0.005.  
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Aim 1, Figure 3 
  
A
hr
C
yp
1b
1
A
ld
h1
a1
0
1
2
3
4
5
R
el
at
iv
e 
m
R
N
A
 L
ev
el
in
 A
LD
H
hi
gh
 C
el
ls *
*****
  
64 
Aim 1, Figure 4: AHR knockdown in Hs578T cells with a chemical 
antagonist and an Ahr-shRNA.  
Wildtype or doxycycline (dox)-inducible shAhr-transduced Hs578T cells 
were transfected with CMV-green control plasmid and AHR-driven pGudLuc 
reporter and treated for 48 hours with 10 µM AHR inhibitor CH223191 or with 
doxycycline (1.5µg/mL) to induce the shAhr. Ahr mRNA was quantified by RT-
qPCR and normalized to Gapdh mRNA expression. pGudLuc activity was 
assayed by luminescence and normalized to CMV-green expression. Values 
were normalized to Ahr or pGudLuc levels in untreated Hs578T cells. Data from 
3-6 experiments are presented as mean + standard error. Asterisks indicate a 
significant decrease in the mRNA fold change or reporter activity, *p<0.01, 
**p<0.001, ***p<0.0001.  
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Aim 1, Figure 4 
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Aim 1, Figure 5: AHR modulation alters ALDH1 activity in Hs578T cells.  
A) Representative flow cytometry plots of ALDEFLUOR™ staining of 
wildtype Hs578T cells or dox-inducible shAhr-transduced Hs578T cells. Dox-
inducible shAhr transduced Hs578T cells were treated for 48 hours with dox. 
Hs578T wildtype cells were treated for 48 hours with vehicle, 10 µM CH223191, 
1 µM β-NF, 0.5 µM FICZ, 1 nM TCDD, or 1 µM DMBA. Regions representing 
ALDHhigh cells were drawn based on the signal generated in the presence of 
DEAB. B) Hs578T cells were treated as in “B” and assayed for the percentage of 
ALDHhigh cells. Data from 6-16 experiments were normalized to results obtained 
with naïve cells (mean baseline = 4.7% ALDHhigh cells) and presented as mean 
fold-change from naive + standard error. Asterisks indicate a significant decrease 
in the percentage of ALDHhigh cells, *p<0.05, **p<0.001, ***p<0.0005. A cross 
indicates a significant increase in ALDHhigh cells, +p<0.05, ++p<0.01, +++p<0.005.  
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Aim 1, Figure 5 
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Aim 1, Figure 6: Representative dot plots after ALDEFLUOR staining.  
Depicted are flow cytometry dotplots of dox-inducible shAhr-transduced 
Hs578T cells without dox (red dots) versus with dox (black dots), wildtype 
Hs578T cells treated with vehicle (red dots) versus CH223191 (black dots), or 
wildtype Hs578T cells treated with vehicle (red dots) versus FICZ (black dots).  
Data are representative of >10 independent experiments.  
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Aim 1, Figure 6 
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Aim 1, Figure 7: AHR modulation alters ALDH activity in immortalized MCF-
10F epithelial cells.  
A) Representative flow cytometry dot plots of ALDEFLUOR™ staining of 
MCF-10F cells treated for 48 hours with vehicle, 10 µM CH223191, or 0.5 µM 
FICZ. Regions representing ALDHhigh cells were drawn based on the signal 
generated in the presence of DEAB. B) MCF-10F cells were treated as in “A” and 
assayed for the percentage of ALDHhigh cells. Data from 4 experiments were 
normalized to results obtained with naïve cells (mean baseline = 0.2% ALDHhigh 
cells) and presented as mean fold-change from naive + standard error. Asterisks 
indicate a significant decrease in the percentage of ALDHhigh cells, *p<0.05, 
**p<0.005. A cross indicates a significant increase in ALDHhigh cells, +p<0.05. 
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Aim 1, Figure 7 
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Aim 1, Figure 8: AHR modulation alters ALDH activity in immortalized MCF-
10A epithelial cells.  
A) Representative flow cytometry dot plots of ALDEFLUOR™ staining of 
MCF-10A cells treated for 48 hours with vehicle, 10 µM CH223191, or 0.5 µM 
FICZ. Regions representing ALDHhigh cells were drawn based on the signal 
generated in the presence of DEAB. B) MCF-10A cells were treated as in “A” and 
assayed for the percentage of ALDHhigh cells. Data from 4 experiments were 
normalized to results obtained with naïve cells (mean baseline = 0.2% ALDHhigh 
cells) and presented as mean fold-change from naive + standard error. Asterisks 
indicate a significant decrease in the percentage of ALDHhigh cells, *p<0.05, 
**p<0.005. A cross indicates a significant increase in ALDHhigh cells, +p<0.05. 
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Aim 1, Figure 9: AHR knockdown in SUM149 cells with a chemical 
antagonist and an Ahr-shRNA.  
Wildtype or dox-inducible shAhr-transduced SUM149 cells were 
transfected, treated and quantified as indicated in Aim, Figure 4. Data from 3-6 
experiments are presented as mean + standard error. Asterisks indicate a 
significant decrease in the mRNA fold change or reporter activity, *p<0.01, 
**p<0.001, ***p<0.0001.  
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Aim 1, Figure 9  
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Aim 1, Figure 10: AHR modulation alters ALDH1 activity in SUM149 cells.  
A) Representative flow cytometry plots of ALDEFLUOR™ staining of dox-
inducible shAhr-transduced SUM149 cells cultured, treated and depicted as 
described in Aim 1, Figure 5A. B) Dox-inducible shAhr-transduced or wildtype 
SUM149 cells were treated, stained and quantified as in Aim 1, Figure 5B. Data 
from 6-12 experiments were normalized to results obtained with naïve cells 
(mean baseline =10.4% ALDHhigh cells) and presented as mean fold-change from 
naive + standard error. Asterisks indicate a significant decrease in the 
percentage of ALDHhigh cells, *p<0.05, **p<0.01, ***p<0.0005. A cross indicates a 
significant increase in ALDHhigh cells, +p<0.01, ++p<0.005.  
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Aim 1, Figure 10 
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Aim 1, Figure 11: Expression of stem cell-associated genes is increased in 
ALDHhigh cells compared to ALDHlow cells.  
Hs578T cells were treated with vehicle for 48 hours, sorted into ALDHhigh 
and ALDHlow cell populations, and then assayed by RT-qPCR for the relative 
levels of the eight stem cell-associated genes indicated. Gene expression was 
then normalized to Gapdh levels and fold-change from vehicle-treated ALDHlow 
cells was calculated. Data from 9 independent experiments are presented as 
means of fold-change + standard error. In all cases, statistical significance was 
determined with the Wilcoxon rank sum test (a paired difference test for when the 
populations are not normally distributed) to conclude if the distributions of results, 
relative to 1 as the standard (represented by the dotted line on each graph), are 
different between the comparison groups. Asterisks indicate a significant 
increase in the mRNA fold change, *p<0.05, **p<0.01, ***p<0.005. Expression 
levels of stem cell-associated genes were normalized to expression levels in 
vehicle-treated ALDHlow cells and the distribution of outcomes from vehicle-
treated ALDHhigh versus vehicle-treated ALDHlow cells compared.  
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Aim 1, Figure 12: AHR hyper-activation increases expression of stem cell-
associated genes in ALDHlow cells.  
Hs578T cells were treated with vehicle or 0.5 µM FICZ for 48 hours, 
sorted into ALDHlow cell populations, and then assayed by RT-qPCR for the 
relative levels of the eight stem cell-associated genes indicated. Gene 
expression was then normalized to Gapdh levels and fold-change from vehicle-
treated ALDHlow cells was calculated. Data from 9 independent experiments are 
presented as means of fold-change + standard error. In all cases, statistical 
significance was determined with the Wilcoxon rank sum test to determine if the 
distributions of results, relative to 1 as the standard (represented by the dotted 
line on each graph), are different between the comparison groups. Asterisks 
indicate a significant increase in the mRNA fold change, *p<0.05, **p<0.01, 
***p<0.005. Stem cell-associated gene expression levels were normalized to 
expression levels in vehicle-treated ALDHlow cells and the distribution of 
outcomes from vehicle-treated ALDHlow versus FICZ-treated ALDHlow cells 
compared. 
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Aim 1, Figure 13: AHR hyper-activation further increases expression of 
stem cell-associated genes in ALDHhigh cells.  
Hs578T cells were treated with vehicle or 0.5 µM FICZ for 48 hours, 
sorted into ALDHhigh cell populations, and then assayed by RT-qPCR for the 
relative levels of the eight stem cell-associated genes indicated. Gene 
expression was then normalized to Gapdh levels and fold-change from vehicle-
treated ALDHhigh cells was calculated. Data from 9 independent experiments are 
presented as means of fold-change + standard error. In all cases, statistical 
significance was determined with the Wilcoxon rank sum test to determine if the 
distributions of results, relative to 1 as the standard (represented by the dotted 
line on each graph), are different between the comparison groups. Asterisks 
indicate a significant increase in the mRNA fold change, *p<0.05, **p<0.01, 
***p<0.005. Stem cell-associated gene expression levels were normalized to 
expression levels in vehicle-treated ALDHhigh cells and the distribution of 
outcomes from vehicle-treated ALDHhigh versus FICZ-treated ALDHhigh cells 
compared. 
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Aim 1, Figure 14: Expression of migration- and invasion-associated genes 
is increased in ALDHhigh cells compared to ALDHlow cells.  
Hs578T cells were treated with vehicle for 48 hours, sorted into ALDHhigh 
and ALDHlow cell populations, and then assayed by RT-qPCR for the relative 
levels of the 7 migration and invasion-associated genes indicated. Gene 
expression was then normalized to Gapdh mRNA levels and fold-change from 
vehicle-treated ALDHlow cells was calculated. Data from 9 independent 
experiments are presented as mean fold-change + standard error. In all cases, 
statistical significance was determined with the Wilcoxon rank sum test to 
determine if the distributions of results, relative to 1 as the standard (represented 
by the dotted line on each graph), are different between the comparison groups. 
Asterisks indicate a significant increase in the mRNA fold change, *p<0.05, 
**p<0.005, ***p<0.0005. Migration and invasion-associated gene expression 
levels were normalized to expression levels in vehicle-treated ALDHlow cells and 
the distribution of outcomes from vehicle-treated ALDHhigh versus vehicle-treated 
ALDHlow cells compared.  
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Aim 1, Figure 15: AHR hyper-activation increases expression of migration- 
and invasion-associated genes in ALDHlow cells.   
Hs578T cells were treated with vehicle or 0.5 µM FICZ for 48 hours, 
sorted into ALDHlow cell populations, and then assayed by RT-qPCR for the 
relative levels of the 7 migration and invasion-associated genes indicated. Gene 
expression was then normalized to Gapdh mRNA levels and fold-change from 
vehicle-treated ALDHlow cells was calculated. Data from 9 independent 
experiments are presented as mean fold-change + standard error. In all cases, 
statistical significance was determined with the Wilcoxon rank sum test to 
determine if the distributions of results, relative to 1 as the standard (represented 
by the dotted line on each graph), are different between the comparison groups. 
Asterisks indicate a significant increase in the mRNA fold change, *p<0.05, 
**p<0.005, ***p<0.0005. Gene expression levels were normalized to expression 
levels in vehicle-treated ALDHlow cells and the distribution of outcomes from 
vehicle-treated ALDHlow versus FICZ-treated ALDHlow cells compared.  
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Aim 1, Figure 16: AHR hyper-activation further increases expression of 
migration- and invasion-associated genes in ALDHhigh cells.  
Hs578T cells were treated with vehicle or 0.5 µM FICZ for 48 hours, 
sorted into ALDHhigh cell population, and then assayed by RT-qPCR for the 
relative levels of the 7 migration and invasion-associated genes indicated. Gene 
expression was then normalized to Gapdh mRNA levels and fold-change from 
vehicle-treated ALDHhigh cells was calculated. Data from 9 independent 
experiments are presented as mean fold-change + standard error. In all cases, 
statistical significance was determined with the Wilcoxon rank sum test to 
determine if the distributions of results, relative to 1 as the standard (represented 
by the dotted line on each graph), are different between the comparison groups. 
Asterisks indicate a significant increase in the mRNA fold change, *p<0.05, 
**p<0.005, ***p<0.0005. Gene expression levels were normalized to expression 
levels in vehicle-treated ALDHhigh cells and the distribution of outcomes from 
vehicle-treated ALDHhigh versus FICZ-treated ALDHhigh cells compared. 
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Aim 1, Figure 17: Ahr and Cyp1b1 expression correlate with expression of 
stem cell- and migration/invasion-associated genes in the CCLE database.  
The gene set enrichment analysis (GSEA) tool 
(http://www.broad.mit.edu/gsea) was used to rank genes from Aim 1, Table 1 
using the cancer cell line encyclopedia (CCLE) dataset (Barretina, et al., 2012) 
based on the correlation of their expression profiles with Ahr (A) and Cyp1b1 (B) 
expression. Considering stem cell- and migration/invasion-associated genes 
present in the CCLE microarray data, their position in the ranked list (represented 
with vertical black lines in the panels) incremented the enrichment score statistic 
(ES, plotted in green). A significant positive correlation between Ahr or Cyp1b1 
and the gene set was demonstrated by GSEA (p=0.025 and 0.021, respectively), 
with Msi1 showing the lowest correlation value in both analyses.  
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Aim 1, Figure 18: Ahr and Cyp1b1 expression correlate with expression of 
stem cell- and migration/invasion-associated genes in the TCGA database.  
 Expression of genes from Aim 1, Table 1 using data from the cancer 
genome atlas (TCGA) dataset (Ma and Ellis, 2013) were ranked based on the 
correlation of their expression profiles with Ahr (A) and Cyp1b1 (B) expression. 
The enrichment score (in green) was computed by considering the position of the 
stem cell- and migration/invasion-associated genes in the ranked list obtained 
from the TCGA RNA-Seq data. A significant positive correlation between 
expression of the putative AHR target genes and Ahr or Cyp1b1 expression 
(p=0.047, p=0.0001, respectively) was demonstrated. The ranking of Msi1 
demonstrated a low correlation with both Ahr and Cyp1b1 expression. 
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Aim 1, Figure 19: AHR down-regulation decreases migration of SUM149 
cells.  
A) Representative images of SUM149 cell migration at 24 and 48 hours 
after cells were sorted into ALDHhigh and ALDHlow populations, cultured to 
confluence, scratched, and treated with vehicle or 10 µM CH223191. Data are 
representative of 4 independent experiments. Black lines indicate the borders of 
the original scratch. B) SUM149 cells were treated as in “A” and percent exposed 
area was quantified. Data from 4 experiments were normalized to results 
obtained with naïve cells and presented as mean percent exposed area + 
standard error. Asterisks indicate a significant increase in exposed area, *p<0.05, 
**p<0.0005. A cross indicates a significant decrease in exposed area, +p<0.05. 
  
  
95 
 
Aim 1, Figure 19 
  
ALDHlow Vehicle ALDHlow CH223191 ALDHhigh Vehicle ALDHhigh CH223191 
24 
hours 
48 
hours 
AL
DH
low
 Ve
hic
le
AL
DH
low
 C
H2
23
19
1
AL
DH
hig
h  V
eh
icl
e
AL
DH
hig
h  C
H2
23
19
1
AL
DH
low
 Ve
hic
le
AL
DH
low
 C
H2
23
19
1
AL
DH
hig
h  V
eh
icl
e
AL
DH
hig
h  C
H2
23
19
1
0
20
40
60
80
N
or
m
al
iz
ed
 %
 E
xp
os
ed
 A
re
a
24 Hours
48 Hours* *
**
*
+
A
B#
  
96 
Aim 1, Figure 20: AHR down-regulation decreases migration of wild-type 
Hs578T and SUM149 cells.  
A) Hs578T cells were plated, cultured to confluence, scratched, and 
treated with vehicle, 10 µM CH223191, or 10 µM CB79983113. Hs578T cell 
migration was measured at 24 and 48 hours and exposed area was quantified. 
Data from 6 experiments were normalized to results obtained with naïve cells 
and presented as mean percent exposed area + standard error. Asterisks 
indicate a significant increase in exposed area, *p<0.05, **p<0.01. B) SUM149 
cells were treated as in “A” and percent exposed area was quantified. Data from 
7 experiments were normalized to results obtained with naïve cells and 
presented as mean percent exposed area + standard error. Asterisks indicate a 
significant increase in exposed area, *p<0.05, **p<0.01.  
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Aim 1, Figure 21: AHR agonists accelerate migration of SUM149 cells.  
A) Representative images of ALDHhigh cell migration at 24 and 48 hours 
after SUM149 cells were sorted into the ALDHlow and ALDHhigh population, 
cultured to confluence, scratched, and treated with vehicle, 0.5 µM FICZ or 1 nM 
TCDD. Data are representative of 5 independent experiments. Black lines 
indicate the borders of the original scratch. B) ALDHlow and ALDHhigh SUM149 
cells were treated as in “A” and percent exposed area was quantified at 24 and 
48 hours. Data from 5 experiments were normalized to results obtained with 
naïve cells and presented as mean percent exposed area + standard error. 
Asterisks indicate a significant decrease in exposed area, *p<0.05, **p<0.01. 
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Aim 1, Figure 22: SUM149 cell proliferation after treatment with AHR 
agonists and antagonists.  
SUM149 cells were stained with CFSE, plated, cultured to confluence, 
scratched, and left untreated or treated with vehicle, 0.5 µM FICZ, 10 µM 
CH223191, or 1 nM TCDD. After 48 hours, fresh SUM149 cells were stained with 
CFSE, and the plated cells were harvested and read on an LSRII flow cytometer 
to determine if proliferation varied among treatment groups. Data is 
representative of three separate experiments. 
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Aim 1, Figure 23: AHR down-regulation decreases Hs578T tumorsphere 
formation.  
A) Dox-inducible shAhr-transduced Hs578T (“shAhr”) or wildtype Hs578T 
cells were left untreated or treated for 48 hours with vehicle, doxycycline, or 10 
µM CH223191 as indicated and cultured in Mammocult media under ultra-low 
adherence conditions. Representative images of primary (day 8) and secondary 
(day 16, following passage at day 8) tumorspheres are presented. The 
percentage of viable cells is included on each image. Data are representative of 
6 independent experiments. B) Hs578T cells were treated as in “A” and 
tumorsphere formation was quantified. Data from 6 experiments were normalized 
to results obtained with naïve cells and presented as mean fold-changes from 
naive + standard error. Asterisks indicate a significant decrease in the 
percentage of tumorspheres, *p<0.05, **p<0.005.  
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Aim 1, Figure 24: AHR down-regulation decreases SUM149 tumorsphere 
formation. 
A) Representative images of primary (day 8) and secondary (day 16) 
tumorspheres after SUM149 cells were treated for 48 hours with vehicle or 10 µM 
CH223191 and plated as described in the methods section.  The percent viable 
cells are included on each image. Data are representative of 5 independent 
experiments. B) SUM149 cells were treated as in “A” and tumorsphere formation 
was quantified. Data from 5 experiments were normalized to results obtained 
with naïve cells and presented as mean fold-change from naive + standard error. 
Asterisks indicate a significant decrease in the percentage of tumorspheres, 
*p<0.05, **p<0.01. 
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Aim 1, Figure 25: AHR down-regulation decreases spheroid formation in 
immortalized MCF-10A epithelial cells.  
MCF-10A sphere formation was quantified. Primary (day 8) and secondary 
(day 16) spheres were quantified after MCF-10A cells were treated for 48 hours 
with vehicle or 10 µM CH223191 and plated as described in the methods section. 
Data are representative of 5 independent experiments. Data were normalized to 
results obtained with naïve cells and presented as mean fold-change from naive 
+ standard error. Asterisks indicate a significant decrease in the percentage of 
tumorspheres, *p<0.05. 
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Aim 1, Figure 26: AHR down-regulation decreases chemotherapeutic 
resistance of both ALDHhigh and ALDHlow Hs578T cells after treatment with 
Adriamycin.  
MTT assays were used to measure cell viability after Hs578T cells were 
sorted into ALDHlow and ALDHhigh populations and treated with Adriamycin with 
and without 10 µM CH223191 for 24 hours. CH223191 treatment alone did not 
affect cell viability (>95% viability in the presence or absence of CH223191). A) 
ALDHlow cells and B) ALDHhigh cells. Data from 7 independent experiments were 
normalized to vehicle-treated cells and presented as mean percent viable cells + 
standard error. Asterisks indicate a significant increase in cell death, *p<0.05, 
**p<0.005, ***p<0.005.  
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Aim 1, Figure 27: AHR down-regulation decreases chemotherapeutic 
resistance of both ALDHhigh and ALDHlow Hs578T cells after treatment with 
Paclitaxel.  
MTT assays were used to measure cell viability after Hs578T cells were 
sorted into ALDHlow and ALDHhigh populations and treated with Paclitaxel with 
and without 10 µM CH223191 for 24 hours. CH223191 treatment alone did not 
affect cell viability (>95% viability in the presence or absence of CH223191).  A) 
ALDHlow cells and B) ALDHhigh cells. Data from 7 independent experiments were 
normalized to vehicle-treated cells and presented as mean percent viable cells + 
standard error. Asterisks indicate a significant increase in cell death, *p<0.05, 
**p<0.005, ***p<0.005.  
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AIM TWO 
Our second aim is to determine the mechanism by which AHR modulation 
affects BCSC population dynamics.   
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AIM TWO METHODS 
Chemicals 
DMSO was obtained from Sigma-Aldrich (St. Louis, MO). 6-
Formylindolo(3,2-b)carbazole (FICZ) was obtained from Santa Cruz 
Biotechnology (Dallas, TX). CH223191 was provided by Dr. M. Pollastri 
(Northeastern University). 
Cell Line Acquisition, Cell Culture, and Media  
Hs578T were purchased from and cultured according to ATCC 
recommendations (ATCC, Manassas, VA). Briefly, Hs578T cells were maintained 
in DMEM Medium (Mediatech, Herndon, VA) containing 5% FBS (Sigma-
Aldrich), 0.0194 M D-Glucose (Sigma-Aldrich), 2 mM L-glutamine (Mediatech), 
100 I.U. penicillin/100 µg/ml streptomycin (Mediatech), 10 µg/ml insulin (Sigma-
Aldrich), and 5 µg/ml Plasmocin (Invivogen, San Diego, CA) at 37°C with 5% 
CO2. 
Chromatin Immunoprecipitation (ChIP) Assay 
ChIP studies were performed using an AHR-specific antibody (ab2769; 
Abcam, Cambridge, MA) and the ChIP kit (ab500; Abcam) according to the 
manufacturer protocol. Cells were fixed and sonicated to produce fragments 
averaging 500 bp. Following immunoprecipitation with AHR-specific antibody or 
normal mouse IgG (Santa Cruz Biotechnology, Dallas, TX), DNA was purified 
and amplified using the following primers: Cyp1b1 primer: 5’-
GTTTGGCGCTGGGTTAC-3’ and 5’-AGGTCGGAGCTGACTCTCT-3’ (Taylor, et 
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al., 2009), Sox2 primer: 5’-CTGTGAGAAGGGCGTGAGAG-3’ and 5’- 
AAACAGCCAGTGCAGGAGTT-3’ and Runx1 pimer: 5’-
TACAAGGCCCGGGAGCAA-3’ and 5’-GCGTTCTTGGGGTCTTTCCT-3’.  
Transient Transfection 
Hs578T cells were transfected with pMXs-Sox2 plasmid (Addgene 
Plasmid #13367) (0.5 µg) (generously provided by Dr. G.  Murphy, Boston 
University) using TransIT-2020 transfection reagent (Mirus, Madison, WI). 
Transfection medium was replaced after 24 hours and cells harvested for 
ALDEFLUOR staining.  
ALDEFLUOR™ Staining 
ALDEFLUOR™ assays were performed according to the manufacturer’s 
instructions (StemCell Technologies, Vancouver, Canada). Cells (106 cells/ml) 
were treated with 5 µl/ml ALDEFLUOR substrate. Negative controls were treated 
with 50 mmol/L diethylaminobenzaldehyde (DEAB), an ALDH-specific inhibitor. 
Samples were incubated for 35 minutes at 37° C and propidium iodine (PI) added 
(1.5 mg/ml) to quantify viability. Cells were assayed with an LSRII flow cytometer 
(Becton Dickinson Biosciences, San Jose, CA) using DEAB controls as 
baselines. Data were analyzed using FlowJo Software (FlowJo, Ashland, OR). 
RT-qPCR  
All RT-qPCR reactions were performed using the GoTaq® RT-qPCR 
Master Mix System (Promega). Validated primers were purchased from Qiagen 
Inc. (Valencia, CA): human Cyp1b1 - QT00209496, Sox2 – QT00237601, Runx1 
  
115 
– QT00026712, and Gapdh – QT01192646. RT-qPCR reactions were performed 
using a 7900HT Fast Real-Time PCR instrument (Applied Biosystems, Carlsbad, 
CA), with hot-start activation at 95° C for 2 min, 40 cycles of denaturation (95° C 
for 15 sec) and annealing/extension (55° C for 60 sec). Relative gene expression 
was determined using the Pfaffl method (Pfaffl, 2001) and the threshold value for 
Gapdh mRNA was used for normalization. The relative DNA amount was 
calculated using the ΔΔCt method. AHR and IgG control pull-down signal were 
normalized to input signal. 
Statistical analyses 
Statistical analyses were performed with StatPlus (Alexandria, VA). Data 
are presented as means + SEMs where applicable. One-way analysis of variants 
(ANOVAs) (simple) were used to determine significance.  
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AIM TWO RESULTS 
AHR alters Sox2 expression, a key gene in CSC biology 
Given the pivotal role of Sox2 in stem cell self-renewal, CSC development 
and breast cancer outcomes (Forghanifard, et al., 2014, Leis, et al., 2011, 
Lengerke, et al., 2011, Liang, et al., 2013, Rodriguez-Pinilla, et al., 2007), 
AHR/Sox2-specific ChIP assays were performed to determine if the AHR directly 
interacts with the Sox2 promoter. Sox2 has seven AHREs, with three AHREs 
within 1500bp of the transcription start site (Aim 2, Figure 1 and Aim 1, Table 1). 
ChIP assays measuring AHR-Cyp1b1 promoter binding served as positive 
controls, with Cyp1b1 having 8 AHREs (Aim 1, Table 1) (Yang, Xinhai, et al., 
2008). Indeed, there was a significant basal level of AHR binding to both Cyp1b1 
and Sox2 promoter fragments (p<0.005-0.0005) (Aim 2, Figure 2), each of which 
contains several AHREs within 500 bp of the PCR primer binding sites (Aim 1, 
Table 1). AHR inhibition with CH223191 significantly decreased AHR-Cyp1b1 
and AHR-Sox2 binding (p<0.01 and p<0.05, respectively). AHR hyper-activation 
with FICZ significantly increased AHR-Cyp1b1 and AHR-Sox2 binding 
approximately 3-fold (p<0.005). These increases were blocked with CH223191 
(p<0.05) (Aim 2, Figure 2).  
Following ChIP assays, the ability of Sox2 to regulate BCSCs was further 
studied to determine the role of Sox2 in BCSC biology. Ectopic SOX2 expression 
significantly increased ALDH1 activity compared to wild-type ALDH1 activity in 
Hs578T cells (p<0.005) (Figure 4). Together, these data strongly suggest that the 
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AHR directly interacts with Sox2, a critical CSC-associated gene, which in turn 
regulates ALDH1 activity, an important marker for BCSCs and an enzyme 
associated with chemoresistance (Croker and Allan, 2011). 
Runx1 is a key player in the mechanism through which AHR modulation 
affects CSCs 
Given the critical role of RUNX1 expression in hematopoiesis and recent 
publications implicating RUNX1 in breast cancer, AHR/Runx1-specific ChIP 
assays were performed to determine if the AHR directly interacts with the Runx1 
promoter (Janes, 2011). Runx1 has thirteen AHREs, with eleven AHREs within 
1500bp of the transcription start site for Runx1 (Aim 2, Figure 5 and Aim 1, Table 
1). ChIP assays measuring AHR-Cyp1b1 promoter binding served as positive 
controls, with Cyp1b1 having 8 AHREs (Aim 1, Table 1) (Yang, Xinhai, et al., 
2008). Indeed, there was a significant basal level of AHR binding to both Cyp1b1 
and Runx1 promoter fragments (p<0.005-0.0005) (Aim 2, Figure 6), each of 
which contains several AHREs within 500 bp of the PCR primer binding sites 
(Aim 1, Table 1). AHR hyper-activation with FICZ significantly increased AHR-
Cyp1b1 and AHR-Runx1 binding approximately 3-fold (p<0.05). This increase 
was blocked with CH223191 (p<0.05) (Aim 2, Figure 6). These data strongly 
suggest that the AHR directly interacts with Runx1, a known regulator of other 
types of stem cells. 
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AIM TWO DISCUSSION 
SOX2 expression is up-regulated in TNBCs and has been implicated in 
tumorsphere formation and control of tumor initiation (Leis, et al., 2011, Liang, et 
al., 2013, Rodriguez-Pinilla, et al., 2007). Additionally, Sox2 has seven AHREs, 
three of which are within 1500 base pairs of the transcription start site (Aim 1, 
Table 1, Aim 2, Figure 1).  It should also be noted that Hs578T FICZ-treated 
ALDHhigh cells had higher expression of Sox2 (Aim 1, Figure 13), with a four-fold 
increase in expression relative to DMSO-treated ALDHlow cells. Using a ChIP 
assay, we found that the AHR directly interacts with the Sox2 promoter (Aim 2, 
Figure 2), which strongly suggests that the AHR is at the apex of an important 
signaling pathway controlled by Sox2. A four-fold increase in Sox2 expression 
was seen following immunoprecipitation after FICZ treatment, while CH223101 
treatment decreased Sox2 expression by half. Together, these findings implicate 
the AHR in the regulation of Sox2, as not only does AHR bind to the Sox2 
promoter, but AHR activity also regulates Sox2 expression. Sox2 has been 
implicated as an important gene that controls cancer progression through 
promoting cell proliferation and tumorigenesis. SOX2 is able to promote 
proliferation and tumorigenesis by facilitating the G1 to S phase transition by up-
regulating cyclin D1 (Chen, et al., 2008).  
Additionally, when cells were transiently transfected with the pMXs-Sox2 
plasmid (Aim 2, Figure 3), the ALDHhigh population increased significantly in 
Hs578T cells (Aim 2, Figure 4). These data imply that the AHR is directly 
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involved in ALDH1 activity, potentially through increasing Sox2 expression.  
Other groups have found that SOX2 is important in BCSC regulation (Leis, et al., 
2011), however what controls Sox2 expression has not been widely studied. 
AHR-Sox2 signaling may be one of the controllers of stem cells signaling in 
general, and CSCs specifically. Further studies need to be done to support these 
findings and to determine to what extent the AHR is controlling Sox2 signaling 
and downstream targets of SOX2 expression, including cyclin D1. 
 RUNX1 is another key transcription factor in stem cell differentiation. 
Previously, RUNX1 expression has been studied for its role in cell fate 
determination in hematopoiesis, osteogenesis and neurogenesis (Chuang, et al., 
2013). Studying the role of RUNX1 in breast cancer and BCSCs is a novel field 
where little research has been done. Recently, Ferrari et al. (2014) found that 
Runx1 expression is a prognostic marker for TNBCs (Ferrari, et al., 2014), 
increasing our interest on the role of Runx1 in BCSCs and the relationship 
between Runx1 and Ahr. Indeed, we saw high levels of Runx1 expression in 
Hs578Ts, with FICZ-treated ALDHhigh cells having higher expression levels of 
Runx1 (Aim 1, Figure 13). Furthermore, Runx1 has thirteen AHREs (Aim 1, Table 
1, Aim 2, Figure 5), including nine AHREs within 1500 base pairs of the 
transcription start site. Due to the number of AHREs, our previous experimental 
findings, and previous studies indicating a potential role for the AHR in stem cell 
and breast cancer biology, we wanted to determine if the AHR directly interacted 
with the Runx1 promoter. Our findings indicate that the AHR binds directly to the 
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Runx1 promoter, and that expression of Runx1 correlates with AHR activity (Aim 
2, Figure 6). These findings support the hypothesis that the AHR may be 
controlling BCSCs through modulating Runx1 expression. Further studies need 
to be performed to determine the role of Runx1 in regulating BCSCs. Studying 
the effect of silencing and over-expressing Runx1 on tumorsphere formation and 
ALDH1 activity will aid in determining the importance of Runx1 in BCSC biology.  
 Much more research needs to be done to fully understand the mechanism 
through which the AHR controls BCSCs. There were a number of genes 
identified in Aim 1 that could be down-stream from the AHR and involved in 
BCSC development that need to be further analyzed. These genes may be 
working individually, in tandem, or in subsets to maintain the BCSC population. 
There are also many other genes, which may or may not be regulated by the 
AHR, that could be controlling BCSCs. Future mechanistic and in vivo studies 
where we explore the role of SOX2 and RUNX1 in tumor formation, proliferation 
and metastasis will help to tease out this complex pathway and determine how 
AHR signaling is controlling BCSC biology.  
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AIM TWO FIGURES 
Aim 2, Figure 1: Relative positions of putative AHREs and amplified 
fragments are presented in the Sox2 promoter.  
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Aim 2, Figure 2: Modulation of AHR activity affects AHR binding to Cyp1b1 
and Sox2 promoters.  
Hs578T cells were treated with vehicle, 10 µM AHR inhibitor CH223191, 
0.5 µM FICZ, or 0.5 µM FICZ + 10 µM CH223191 for 48 hours and ChIP assays 
were performed with human AHR-specific antibody and Cyp1b1- or Sox2-specific 
promoters as described in the Materials and Methods. Data from 5 independent 
experiments are presented as mean fold-change + standard error. An asterisk 
indicates a significant increase relative to vehicle controls, *p<0.005. A pound 
sign indicates a significant decrease relative to vehicle controls, #p<0.05, 
##p<0.01. A cross indicates a significant increase relative to IgG controls, 
+p<0.005, ++p<0.0005. A caret sign indicates a significant decrease relative to 
FICZ treatment, ^p<0.05.  
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Aim 2, Figure 3: pMXs-Sox2 Map.  
Hs578T cells were transfected with a pMXs-Sox2 plasmid to ectopically 
express SOX2. 
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Aim 2, Figure 3 
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Aim 2, Figure 4: Transient Sox2 transfection increases ALDH activity.  
Hs578T cells were transfected with a pMXs-Sox2 plasmid and ALDH 
activity assayed 48 hours later. Data from 4 independent experiments are 
presented as percent ALDHhigh + standard error. Asterisk indicates a significant 
increase in the percent ALDHhigh cells, *p<0.005. 
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Aim 2, Figure 5: Relative positions of putative AHREs and amplified 
fragments are presented in the Runx1 promoter.  
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Aim 2, Figure 6: Modulation of AHR activity affects AHR binding to Cyp1b1 
and Runx1 promoters.  
Hs578T cells were treated with vehicle, 0.5 µM FICZ, or 0.5 µM FICZ + 10 
µM CH223191 for 48 hours and ChIP assays were performed with human AHR-
specific antibody and Cyp1b1- or Runx1-specific promoters as described in the 
Materials and Methods. Data from 4-5 independent experiments are presented 
as mean fold-change + standard error. An asterisk indicates a significant 
increase relative to vehicle controls, *p<0.05. A cross indicates a significant 
increase relative to IgG controls, +p<0.05, ++p<0.0001. A caret sign indicates a 
significant decrease relative to FICZ treatment, ^p<0.05.  
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Aim 2, Figure 6  
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AIM THREE 
Our third aim is to define the functional relevance of AHR signaling in 
BCSC biology in an in vivo model. 
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AIM THREE METHODS 
Mouse Model  
Eight-week old female NOD-SCID mice were purchased from Jackson 
Laboratory (Bar Harbor, ME). To determine if the AHR influences the 
tumorigenicity of CSCs, SUM149 cells, stably transduced with a dox-inducible 
shAhr were sorted and 5,000 ALDHhigh and ALDHlow cells in 100 µL of 50:50 
Matrigel/DMEM were injected into the right and left mammary fat pads, 
respectively, of 20 female non-obese diabetic-severe combined 
immunodeficiency (NOD-SCID) mice. Ten control mice drank water with 5% 
sucrose, while ten mice were provided with water containing 2 mg/mL 
doxycycline and 5% sucrose to induce the shAhr. Tumor growth was monitored 
and measured externally using Vernier calipers and animals were sacrificed 
when the total tumor burden reached 15 mm in size.  
Necropsies were performed to dissect out the tumors from both sides. 
RNA was isolated from each of the primary tumors for analysis. Animals were 
housed at the Association for Assessment and Accreditation of Laboratory 
Animal Care certified Boston University Medical Laboratory Animal Science 
Center and used in accordance with the National Institute of Health’s Guide for 
the Care and Use of Laboratory Animals. A Boston University Medical Campus 
Institutional Animal Care and Use Committee approved the protocol and National 
Institutes of Health Guide for the Care and Use of Laboratory Animals was 
followed.  
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ALDEFLUOR™ Staining 
ALDEFLUOR™ assays were performed according to the manufacturer’s 
instructions (StemCell Technologies, Vancouver, Canada). Cells (106 cells/ml) 
were treated with 5 µl/ml ALDEFLUOR substrate. Negative controls were treated 
with 50 mmol/L diethylaminobenzaldehyde (DEAB), an ALDH-specific inhibitor.  
Samples were incubated for 35 minutes at 37° C. ALDHhigh and ALDHlow cells 
were sorted on a MoFlo Legacy (Beckman Coulter, Indianapolis, IN). 
RT-qPCR  
 mRNA was extracted using RNeasy® Plus Mini Kit (Qiagen, Valencia, CA) 
and cDNA prepared using the GoScript™ Reverse Transcription System 
(Promega, Madison, WI) with a 1:1 mixture of random and Oligo (dT)15 primers. 
All RT-qPCR reactions were performed using the GoTaq® RT-qPCR Master Mix 
System (Promega). Validated primers were purchased from Qiagen Inc. 
(Valencia, CA): human Cyp1b1 - QT00209496, Aldh1a1 – QT00013286, Sox – 
QT00237601, Ahr – QT02422938, and Gapdh – QT01192646. RT-qPCR 
reactions were performed using a 7900HT Fast Real-Time PCR instrument 
(Applied Biosystems, Carlsbad, CA), with hot-start activation at 95° C for 2 min, 
40 cycles of denaturation (95° C for 15 sec) and annealing/extension (55° C for 
60 sec). Relative gene expression was determined using the Pfaffl method 
(Pfaffl, 2001) and the threshold value for Gapdh mRNA was used for 
normalization.  
Statistical analyses 
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Statistical analyses were performed with StatPlus (Alexandria, VA) unless 
otherwise noted. Data are presented as means + SEMs where applicable. One-
way analysis of variants (ANOVAs) (simple) was used to determine significance.  
Statistical analyses of the mouse model compared the average rate of 
change over time between groups using a random effects model with a random 
intercept for each mouse. Day 22 was used as the starting (baseline) value to 
calculate the rate of change. All analyses were performed using SAS v9.3 using 
a 0.05 level of significance. 
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AIM THREE RESULTS 
AHR knockdown decreases tumor growth and Ahr, Cyp1b1, Aldh1a1, and 
Sox2 expression in vivo  
 CSCs tend to generate more aggressive cancers that grow faster than 
non-CSCs (Al-Hajj, et al., 2003, Charafe-Jauffret, et al., 2010, Charafe-Jauffret, 
et al., 2009, Fillmore and Kuperwasser, 2008, Wicha, et al., 2003). To determine 
if the AHR influences this parameter of CSCs, SUM149 cells, stably transduced 
with a dox-inducible shAhr (Aim 1, Figure 9), were sorted and 5,000 ALDHhigh 
and ALDHlow cells were injected into the right and left mammary fat pads, 
respectively, of female NOD-SCID mice. Half of the mice were given doxycycline-
containing water to induce the shAhr (Aim 3, Figure 1). Consistent with previous 
studies demonstrating CSC plasticity (Chaffer, et al., 2011),  sorted Hs578T 
subpopulations reverted to the original distribution of ALDHhigh (~5%) and 
ALDHlow (~95%) cells after 24 hours (Aim 3, Figure 2C and 2D). However, sorted 
SUM149 cells were fairly stable over 96 hours, and therefore used for our in vivo 
experiment (Aim 3, Figure 2A and 2B). 
SUM149 ALDHhigh cells generated palpable tumors more rapidly and 
these tumors grew at a significantly faster rate than ALDHlow cells (growth rates 
of 0.26 vs 0.19 mm/day, p<0.0001) (Aim 3, Figure 3A). Furthermore, dox-induced 
shAhr significantly reduced growth rates from 0.26 to 0.18 and from 0.19 to 0.11 
mm/day in ALDHhigh and ALDHlow cells respectively (p<0.0005) (Figure 3B, 3C), 
resulting in significantly improved survival over the course of the experiment 
  
138 
(p<0.05) (Aim 3, Figure 4). Consistent with in vitro experiments, Ahr, Cyp1b1, 
Aldh1a1, and Sox2 mRNA levels were significantly reduced in tumors from 
doxycycline-treated mice (p<0.05-0.005) (Aim 3, Figure 5). Runx1 expression 
was not significantly decreased following AHR knockdown in vivo (Aim 3, Figure 
5). These results indicate that ALDHhigh cells resemble CSC/tumor-initiating cells 
and that the AHR controls the growth rate and stem cell-associated gene 
expression of CSCs in vivo. 
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AIM THREE DISCUSSION  
Analogous to the in vitro studies performed in Chapter 1 and Chapter 2, 
tumors formed in vivo from ALDHhigh cells were detected sooner and grew faster 
than those generated with ALDHlow cells (Aim 3, Figure 3A). AHR knockdown 
significantly slowed the growth of ALDHlow and ALDHhigh cell-derived tumors (Aim 
3, Figure 3B and 3C). Overall, mice that were grafted with tumor cells in which 
the AHR was down-regulated survived longer than mice where the shAHR was 
not induced (Aim 3, Figure 4).  
It should be noted that the ability of CSCs to revert back and forth 
between the BCSC and bulk/progenitor population phenotype may affect the rate 
of tumor growth in vivo (Aim 3, Figure 1) (Chaffer, et al., 2011). We used 
SUM149 cells in this experiment to try to minimize the potential for cell reversion, 
as Hs578T cells reverted back to their baseline ALDHhigh and ALDHlow 
populations after 24 hours (Aim 3, Figure 2C and 2D). SUM149 cells maintained 
their ALDHhigh and ALDHlow phenotype for at least 96 hours after sorting (Aim 3, 
Figure 2A and 2B). At around day 39 of our in vivo experiment, it appears as 
though the growth rate of ALDHlow cells reverts to that of ALDHhigh cells (Aim 3, 
Figure 3A and 3B). This could be due to the sorted ALDHlow cells reverting back 
to the baseline of 10% ALDHhigh cells (Aim 1, Figure 10). This reversion of sorted 
cells allows for the growth rate of sorted ALDHhigh and ALDHlow populations to 
equalize over time, potentially confounding our findings.  The ability to control for 
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reversion of the cells in vivo and therefore control for the change in growth rates 
would allow us to further explore the role of AHR signaling in BCSC biology. 
Further experiments must be performed to determine if the decrease in 
tumor growth rate was due to generalized inhibition of cell growth by AHR 
knockdown, and/or due to CSCs differentiating into progenitor cells after shAHR-
mediated knockdown and losing their increased growth rate and metastatic 
capabilities. The first step towards understanding the mechanism behind this 
decrease in tumor growth rate was harvesting the tumors from the experimental 
mice, followed by probing for mRNA expression via RT-qPCR. Mice treated with 
doxycycline to knockdown AHR expression all had decreased expression of Ahr, 
Cyp1b1, Sox2 and Aldh1a1 (Aim 3, Figure 5). However, it should be noted that 
no change was seen in Runx1 expression in this in vivo setting (Aim 3, Figure 5). 
No significant difference in Runx1 expression between the two groups may be 
due to BCSC plasticity, too few mice to reach significance, or experimental 
outliers that skewed the results. 
A significant decrease in Ahr and AHR-regulated Cyp1b1 expression was 
expected after induction of Ahr-specific shRNA, as shown in Aim 1 (Figure 9). 
Doxycycline treatment did in fact lead to decreased Ahr expression and Cyp1b1 
expression in vivo (Aim 3, Figure 5A and 5B). The ten mice that received 
doxycycline to induce the shRNA against AHR decreased their expression of Ahr 
and Cyp1b1 by half. It is possible that a greater knockdown of Ahr expression 
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may lead to more robust outcomes, with larger changes in growth rates and 
survivability between treatment groups. 
Based on our ALDH1 activity assays (Aim 1, Figures 5 and 10), we 
expected to see a decrease in Aldh1a1 expression following AHR knockdown. 
We found a significant decrease in Aldh1a1 expression between treatment 
groups in our in vivo model (Aim 3, Figure 5C). We hypothesize that this 
difference in expression is directly correlated to the knockdown of AHR based on 
these findings in vivo and the similar findings in vitro (Aim 1, Figure 10). 
Finally, we observed a significant decrease in Sox2 expression following 
AHR knockdown in vivo (Aim 3, Figure 5D).  Verifying that Sox2 expression 
decreased after AHR knockdown validated our ChIP findings, which found that 
the AHR is directly binding to the Sox2 promoter and regulating its expression 
(Aim 2, Figure 2). These findings indicate that Sox2 may be a key regulator in our 
system, and a target that we should continue to explore. In the future, studying 
the role of AHR activity in Sox2 expression, ALDH1 activity, and tumorsphere 
formation, as well as the effect of altered Sox2 expression on in vivo tumor 
formation, would be an important first step in elucidating how AHR-Sox2 
signaling is affecting BCSC biology. Previous in vivo studies have found that 
overexpression of Sox2 leads to an increase in tumor growth rate, while a 
knockdown of Sox2 leads to a decrease in tumor growth rate and volume (Chen, 
et al., 2008). Our findings support the work of Chen et al. (2008), while also 
implying that AHR signaling is the key factor controlling Sox2 expression 
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upstream. We have shown that the AHR directly binds to the promoter of Sox2, 
but further mechanistic studies need to be performed to further elucidate how 
that interaction leads to a change in BCSC biology. 
There are many in vivo studies that still need to be performed to further 
clarify the role of the AHR in BCSC biology. Replicating the above study with 
increased animal numbers and probing for additional markers after tumor 
harvest, such as NOTCH1, NOTCH2, SLUG, SNAIL, TWIST and VIM, will help 
increase statistical power, to reach significance for RUNX1, and allow for further 
exploration of how the AHR is controlling BCSCs. Another important next step 
would be in vivo experiments studying AHR modulation in conjunction with 
chemotherapy treatment. Based on our in vitro findings (Aim 1, Figure 26 and 
27), we believe that AHR modulation will lead to increased chemotherapy 
efficacy. Finally, it would be interesting to knockdown or overexpress potential 
down-stream markers that we hypothesize the AHR is controlling, such as SOX2 
and RUNX1, and monitoring tumor formation in vivo. In vivo experimentation is a 
key step in translating in vitro findings directly to the most important stakeholder, 
breast cancer patients with TNBC and IBC who lack viable treatment options.  
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AIM THREE FIGURES 
Aim 3, Figure 1: Schematic of the in vivo murine model.  
Female NOD-SCID mice were injected with 5,000 ALDHhigh SUM149 cells 
into the right mammary fat pad, and with 5,000 ALDHlow SUM149 cells into the 
left mammary fat pad. The SUM149 cells had been transduced with a 
doxycycline inducible AHR-shRNA, which was induced by doxycycline 
administered in the mouse drinking water. Tumor growth was measured with 
calipers every second day. 
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Aim 3, Figure 2: SUM149 and Hs578T cells revert back to baseline ALDH 
populations after sorting.  
A-B) SUM149 cells were sorted into ALDHhigh and ALDHlow populations 
and treated for 96 hours with vehicle or 10 µM CH223191. Every 24 hours, cells 
were assayed for percent ALDHhigh and ALDHlow to determine how quickly cells 
reverted to the baseline percentages of ALDHhigh and ALDHlow cell populations. 
C-D) Hs578T cells were sorted into ALDHhigh and ALDHlow populations and 
treated for 24 hours with vehicle. After 24 hours, cells were assayed for percent 
ALDHhigh to determine how quickly cells reverted to the baseline percentages of 
ALDHhigh and ALDHlow cell populations. 
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Aim 3, Figure 3: AHR down-regulation decreases tumor formation in mice 
with human xenografts.  
A) Growth of tumors initiated with ALDHhigh cells as compared with 
ALDHlow cells. Data are presented as mean tumor volume + standard error. 
p<0.0001. The average rate of tumor growth of the ALDHhigh cells in control mice 
(0.22 mm/day) was significantly different than that of ALDHlow cells in dox-treated 
mice (0.15 mm/day), p<0.0005. A cross indicates a significant increase in 
ALDHhigh average tumor size compared to ALDHlow tumors at day 25, +p<0.01. B) 
Growth of tumors initiated with dox-inducible-shAhr transduced ALDHlow cells in 
mice given water alone or water + doxycycline. Average rate of tumor growth of 
ALDHlow cells in control mice (0.19 mm/day) was significantly different than that 
of ALDHlow cells in dox-treated mice (0.11 mm/day), p<0.0005. C) Growth of 
tumors initiated with dox-inducible shAhr-transduced ALDHhigh cells comparing 
mice given water alone or water + doxycycline. Average rate of tumor growth of 
the ALDHhigh cells in control mice (0.26 mm/day) was significantly different than 
ALDHhigh cells in dox-treated mice (0.18 mm/day), p<0.0005. A cross indicates a 
significant increase in dox-inducible shAhr-transduced ALDHhigh cell-derived 
tumors in control mice as compared with dox-treated mice at day 25, +p<0.01.  
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Aim 3, Figure 3 
  
24 28 32 36 40 44 48 52 56
0
2
4
6
8
10
12
Days Post Injection
A
ve
ra
ge
 T
um
or
 S
iz
e 
(m
m
)
ALDHhigh no dox
ALDHhigh + dox
+
24 28 32 36 40 44 48 52 56
0
2
4
6
8
10
12
Days Post Injection
A
ve
ra
ge
 T
um
or
 S
iz
e 
(m
m
)
ALDHhigh no dox
ALDHlow no dox
+
24 28 32 36 40 44 48 52 56
0
2
4
6
8
Days Post Injection
A
ve
ra
ge
 T
um
or
 S
iz
e 
(m
m
)
ALDHlow no dox
ALDHlow + dox
A 
C 
B 
  
149 
Aim 3, Figure 4: AHR down-regulation significantly reduces time to death in 
mice with human xenografts.  
Survival of control mice as compared with dox-treated mice is shown. 
Mice were sacrificed when the total tumor burden reached 15 mm. *p<0.05 
(Gehan-Breslow-Wilcoxon test).  
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Aim 3, Figure 5: AHR down-regulation decreases expression of Ahr, 
Aldh1a1, Cyp1b1 and Sox2 in mouse tumors, but not Runx1 expression.  
Tumors were harvested after 42-72 days when they reached 15 mm in 
total size. RNA was extracted from each tumor. A) Ahr, B) Cyp1b1, C) Aldh1a1, 
D) Sox2, and E) Runx1 mRNA expression levels were assayed by RT-qPCR. 
Since the AHR controls expression of Cyp1b1, Aldh1a1, and Sox2 in both 
ALDHhigh and ALDHlow cells (e.g., Aim 3, Figure 3), data generated with tumors 
from ALDHhigh and ALDHlow tumors were pooled for statistical purposes. Data are 
presented as fold-change relative to the average CT value from control treated 
mice injected (no dox) with ALDHlow cells + SE. Asterisks indicate a significant 
decrease in the mRNA fold change, *p<0.05, **p<0.01, ***p<0.005. 
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Aim 3, Figure 5 
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OVERALL CONCLUSIONS 
  Results presented here are indicative of several studies suggesting that 
baseline (endogenous ligand-induced) AHR activity in immortalized cells favors 
TNBC tumor growth or aggressive behavior (Barhoover, et al., 2010, Brooks and 
Eltom, 2011, Chang, et al., 2007, Goode, et al., 2014, Goode, et al., 2013, Opitz, 
et al., 2011, Powell, et al., 2013). Paradoxically, several studies indicate that 
exogenous AHR ligands can reduce tumor growth or invasion (Abdelrahim, et al., 
2003, Barhoover, et al., 2010). These seemingly contradictory results may in part 
reflect cell type-specific differences. For example, AHR agonists may inhibit 
growth in ER+ breast cancers in part through AHR-mediated down-regulation of 
ER expression or activity (Abdelrahim, et al., 2003). But in similar cell types (Hall, 
et al., 2010, Prud'homme, et al., 2010, Subramaniam, et al., 2011), similar AHR 
agonist- and antagonist-mediated outcomes could be due to less pronounced 
effects on AHR activation or signaling.  
  For instance, it has been postulated that while endogenous AHR ligands 
drive signaling towards, for example, increased invasion, exogenous AHR 
ligands “divert” (Schlezinger, et al., 2006) or “disrupt” (Barhoover, et al., 2010) 
the response towards signaling pathways which oppose tumor invasion, e.g. 
differentiation (Hall, et al., 2010). Furthermore, exogenous ligands, e.g., 
Tranilast, that decrease invasion (Prud'homme, et al., 2010, Subramaniam, et al., 
2011), may act as partial agonists that compete with endogenous ligands for 
AHR binding, but which are weaker activators of AHR transcriptional activity, 
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thereby reducing baseline AHR signaling (Howard, et al., 2010). Finally, 
outcomes may be ligand-, cell subset-, or dose-specific. Thus, high affinity AHR 
ligands such as TCDD induce stem cell characteristics including ALDH 
expression and accelerated migration, particularly at low doses (e.g., 0.2-1 nM) 
(Aim 1, Figure 21), while higher doses (10 nM) reduce invasiveness of the 
majority non-CSC population (Hall, et al., 2010). Clearly, further experimentation 
is required to resolve this issue.   
  Collectively, these studies indicate that the AHR influences critical 
functions of CSCs that contribute to cancer recurrence and metastasis. The 
ability of several exogenous AHR ligands, including TCDD and DMBA, to up-
regulate phenotypic, genomic, and/or functional markers of CSCs strongly 
suggests the potential for ubiquitous environmental AHR ligands, perhaps 
preferentially at low doses, to accelerate progression to lethal, metastatic 
cancers. Furthermore, the demonstration that AHR inhibition reduces expression 
of these markers encourages the testing of AHR inhibitors, such as CH223191 
and CB7993113, as a mechanism to significantly increase the sensitivity of CSCs 
to conventional chemotherapeutics. In general, these results suggest that non-
toxic AHR modulators may represent important therapeutics for otherwise 
refractory TNBC, IBC, and potentially for brain and other cancers in which the 
AHR also appears to play a role (Litzenburger, et al., 2014, Opitz, et al., 2011, 
Rinaldi, et al., 2002, Tsay, et al., 2013). 
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